

Synthesis of C5-Allylindoles through an Iridium-Catalyzed Asymmetric Allylic Substitution/Oxidation Reaction Sequence of N-alkyl Indolines

Jiamin Lu[†], Ruigang Xu[†], Haixia Zeng, Guofu Zhong*, Meifang Wang, Zhigang Ni, and Xiaofei Zeng*

College of Materials, Chemistry and Chemical Engineering, Hangzhou Normal University, Hangzhou 310036, China

Table of Contents

I	General Information.....	S2
II	Optimization of Reaction Conditions.....	S3
III	Experimental Sections.....	S7
IV	Characterization of Products.....	S15
V	Transformations of Compound 4a	S44
VI	Enantiodivergent Synthesis of Compound 9a-d	S47
VII	Synthesis of Chiral Analogue 11	S50
VIII	Absolute Configuration of 3a	S52
IX	Data of NMR Spectra.....	S55
X	Data of HPLC Chromatography.....	S104

I General information:

Analytical thin layer chromatography (TLC) was performed using Merck 60 F254 precoated silica gel plate (0.2 mm thickness). Subsequent to elution, plates were visualized using UV radiation (254 nm) on Spectroline Model ENF-24061/F 254 nm. Further visualization was possible by staining with basic solution of potassium permanganate or acidic solution of ceric molybdate.

Flash column chromatography was performed using Merck aluminium oxide90 active neutral with freshly distilled solvents. Columns were typically packed as slurry and equilibrated with the appropriate solvent system prior to use.

Proton nuclear magnetic resonance spectra (^1H NMR) were recorded on Bruker AMX 500 spectrophotometer (CDCl_3 as solvent). Chemical shifts for ^1H NMR spectra are reported as δ in units of parts per million (ppm) downfield from SiMe_4 (0.0) and relative to the signal of chloroform-d (7.26, singlet). Multiplicities were given as: s (singlet), d (doublet), t (triplet), dd (doublets of doublet) or m (multiplets). The number of protons (n) for a given resonance is indicated by nH. Coupling constants are reported as a J value in Hz. Carbon nuclear magnetic resonance spectra (^{13}C NMR) are reported as δ in units of parts per million (ppm) downfield from SiMe_4 (0.0) and relative to the signal of chloroform-d (77.0, triplet).

Enantiomeric excesses were determined by high performance liquid chromatography (HPLC) analysis on a chiral stationary phase, CHIRALCEL OD-H, CHIRALCEL IC or CHIRALCEL AD-H. Optical rotations were measured in CHCl_3 on a Schmidt + Haensdchpolarimeter (Polartronic MH8) with a 10 cm cell (c given in g/100 mL).

High resolution mass spectrometry (HRMS) was recorded on QTOF perimer for ESI^+ .

II Optimization of reaction conditions:

Table S1. Screening of various chiral phosphoramidite ligands^a

The reaction scheme shows the conversion of indole **1a** and chiral alcohol **(±)-2a** to product **3a** under specific reaction conditions. The conditions are: $[\text{Ir}(\text{COD})\text{Cl}]_2$ (2 mol%), Ligand (8 mol%), $\text{BF}_3 \cdot \text{Et}_2\text{O}$ (30 mol%), THF (0.2 M), 12 h, r.t. The products are shown with a blue double bond indicating stereochemistry.

entry	ligand	yield (%) ^b	ee (%) ^c
1	(R)-L1	67	96
2	(R)-L2	n.r.	-
3	(R)-L3	n.r.	-
4	(R)-L4	n.r.	-
5	(R)-L5	< 5	-

^aReaction conditions: 2 mol% of $[\text{Ir}(\text{COD})\text{Cl}]_2$, 8 mol% of ligand, 30 mol% of $\text{BF}_3 \cdot \text{Et}_2\text{O}$, 0.2 mmol of **1a**, 0.4 mmol of **2a** in THF (0.2 M) at room temperature, 12 h. ^bIsolated yields of **3a**. ^cDetermined by HPLC analysis. n.r. = no reaction, n.d. = not determined.


Table S2. Comparison of various solvents^a

The reaction scheme shows the conversion of indole **1a** and chiral alcohol **(±)-2a** to product **3a** under specific reaction conditions. The conditions are: $[\text{Ir}(\text{COD})\text{Cl}]_2$ (2 mol%), **(R)-L1** (8 mol%), $\text{BF}_3 \cdot \text{Et}_2\text{O}$ (30 mol%), Solvent (0.2 M), 12 h, r.t. The products are shown with a blue double bond indicating stereochemistry.

entry	solvent	yield (%) ^b	ee (%) ^c
1	THF	67	96
2	DCM	74	81
3	DCE	83	80
4	Dioxane	68	97
5	Et_2O	57	95
6	Toluene	60	96
7	CH₃CN	62	98
8	MTBE	56	97

^aReaction conditions: 2 mol% of $[\text{Ir}(\text{COD})\text{Cl}]_2$, 8 mol% of **(R)-L1**, 30 mol% of $\text{BF}_3 \cdot \text{Et}_2\text{O}$, 0.2 mmol of **1a**, 0.4 mmol of **2a** in solvents (0.2 M) at room temperature, 12 h. ^bIsolated yields of **3a**.


^cDetermined by HPLC analysis.

Table S3. Comparison of various acid promoters^a

entry	acid	yield (%) ^b	ee (%) ^c
1	BF ₃ ·Et ₂ O	62	98
2	(PhO) ₂ POOH	71	99
3	(CF ₃ SO ₂) ₂ NH	72	96
4	(±) - CSA	69	99
5	CF ₃ COOH	67	99
6	La(OTf) ₃	42	> 99
7	Fe(OTf) ₂	22	98
8	Sc(OTf) ₃	48	84
9	Zn(OTf) ₂	12	96

^aReaction conditions: 2 mol% of [Ir(COD)Cl]₂, 8 mol% of (R)-L1, 30 mol% of acid promoters, 0.2 mmol of 1a, 0.4 mmol of 2a in CH₃CN (0.2 M) at room temperature, 12 h. ^bIsolated yields of 3a.


^cDetermined by HPLC analysis. (±) - CSA = (±) - camphorsulfonic acid, n.r. = no reaction, n.d. = not determined.

Table S4. Comparison of the equivalent of starting materials^a

entry	x	yield (%) ^b	ee (%) ^c
1	2.0	71	99
2	1.0	31	95
3	1.2	53	> 99
4	1.5	56	> 99
5	2.5	72	> 99
6	0.5	57	98
7	0.67	35	96
8	0.83	37	> 99

^aReaction conditions: 2 mol% of [Ir(COD)Cl]₂, 8 mol% of (R)-L1, 30 mol% of (PhO)₂POOH, 0.2 mmol of 1a, x equivalent of 2a in CH₃CN (0.2 M) at room temperature, 12 h. ^bIsolated yields of 3a.


^cDetermined by HPLC analysis.

Table S5. Comparison of the equivalent of acid promoters^a

entry	x	yield (%) ^b	ee (%) ^c
1	30	72	> 99
2	10	40	96
3	20	83	> 99
4	40	72	> 99

^aReaction conditions: 2 mol% of $[\text{Ir}(\text{COD})\text{Cl}]_2$, 8 mol% of $(\text{R})\text{-L1}$, x mol% of $(\text{PhO})_2\text{POOH}$, 0.2 mmol of **1a**, 0.5 mmol of **2a** in CH_3CN (0.2 M) at room temperature, 12 h. ^bIsolated yields of **3a**.


^cDetermined by HPLC analysis.

Table S6. Comparison of the equivalent of $[\text{Ir}(\text{COD})\text{Cl}]_2$ and ligand^a

entry	x	y	yield (%) ^b	ee (%) ^c
1	2	8	83	> 99
2	1	4	18	94
3	1.25	5	21	95
4	1.5	6	68	> 99

^aReaction conditions: x mol% of $[\text{Ir}(\text{COD})\text{Cl}]_2$, y mol% of $(\text{R})\text{-L1}$, 20 mol% of $(\text{PhO})_2\text{POOH}$, 0.2 mmol of **1a**, 0.5 mmol of **2a** in CH_3CN (0.2 M) at room temperature, 12 h. ^bIsolated yields of **3a**.

^cDetermined by HPLC analysis.

Table S7. Comparison of the solvent's concentration^a

entry	x	yield (%) ^b	ee (%) ^c
1	0.20	83	> 99


2	0.10	82	> 99
3	0.15	87	> 99
4	0.25	93	> 99

^aReaction conditions: 2 mol% of [Ir(COD)Cl]₂, 8 mol% of (*R*)-**L1**, 20 mol% of (PhO)₂POOH, 0.2 mmol of **1a**, 0.5 mmol of **2a** in CH₃CN (0.25 M) at room temperature, 12 h. ^bIsolated yields of **3a**.

^cDetermined by HPLC analysis.

III Experimental section


3.1. General synthesis for *Carreira* ligand (*R*)-**L1**:



Scheme S1. Synthesis of *Carreira* ligand (*R*)-**L1**

The synthetic protocol of *Carreira* ligand was accorded to the relevant literature¹. To an oven-dried flask charged with stir bar and **S1** (1.574 g, 5.5 mmol), then refilled with argon 3 times. Redistilled PCl_3 (5.76 mL, 66.0 mmol, 12.0 equiv) and DMF (12.6 μL , 0.165 mmol, 0.03 equiv) were added sequentially. The system was oil bath heated to 55°C smoothly and stirred for 1.5 hour to give colorless oil. After reaction completion, the excess PCl_3 was removed under the reduced pressure to afford product **S2** with white foam, then dissolved in 200 mL anhydrous THF. **S3** (prepared from iminostilbene and *n*-BuLi) in 50 mL THF was added dropwise to the above solution via syringe at -78°C . The dark blue homogeneous solution was warmed to room temperature slowly and stirred for additional 6-8 h. Afterwards, the organics was quenched by water. The mixture was extracted with EtOAc 3 times, then separated. The organic mixture was washed with water and brine, then dried over anhydrous Na_2SO_4 and concentrated *in vacuo*. The residue was purified by silica gel column chromatography with eluent (PE/EA/Et₃N = 20/1/0.1% to 8/1/0.1%) to give the final product, then recrystallized with DCM/pentane to afford the high ee value (>99%) compound (*R*)-**L1**. The characterization data of compound (*R*)-**L1** was reported as reference.


3.2. General synthesis for allylic alcohols:




Scheme S2. Synthesis for allylic alcohols

The synthetic protocol of branched allylic alcohols was according to the relevant literature². Aryl aldehyde was added to an oven-dried round bottom flask and refilled with argon twice times, followed by the addition of anhydrous THF solvent (0.1 M). After completely cooled to -40°C , vinylmagnesium bromide (1.2 equiv, 1.0 M in THF) was then added slowly via syringe. The system was warmed to 0°C and stirred for extra 4~8 h. The organic mixture was quenched by the saturated aqueous NH_4Cl and extracted with EtOAc twice times. The organic phase was separated and washed with water and brine, dried over anhydrous Na_2SO_4 , filtrated, concentrated under then reduced pressure. The residue was purified by flash chromatography ($\text{PE:EA}=10:1$) to give the desired product. The characterization data of allylic alcohols were reported as reference.


3.3. General procedure for the synthesis for *N*-protected hydro-heterocyclic compounds:





Scheme S3. Synthesis of allylic alcohols indolines

The synthetic protocol of substituted indolines **1b-1l**, **1k**, **1l**, **1n-1p** was according to the relevant literature³. Compounds **1j**, **1m** were synthesized according to the following method. At ambient temperature, to a 50 mL of oven-dried flask, commercially available substituted indole (8 mmol) was added glacial acetic acid (16 mL). After completely dissolved, NaBH₃CN (2.0 equiv) was added portionwise. Afterwards, the organic mixture was stirred for 2~6 h. The solvent was removed under the reduced pressure, and the residue was treated by the 1.0 M aqueous NaOH. The mixture was extracted with DCM twice times before separated. The organic layer was washed with water and brine, dried over Na₂SO₄, filtrated, concentrated *in vacuo*. The crude product was purified by column chromatography (PE/EA) to afford the desired compound.




Scheme S4. Synthesis of *N*-protected indoles

The synthetic protocol of *N*-Bn indolines/*N*-Bn hydroheterocyclic compounds were accorded to the relevant literature⁴. To a two-necked flask charged with stir bar and indolines/hydroheterocyclic compounds (5 mmol) was added saturated aqueous NaHCO₃ (20 mL) and oil bath heated to 95°C slowly. BnBr (1.05 equiv) was added dropwise over 5 min to the above solution and stirred vigorously for additional 2 h. After completion, the reaction mixture was extracted with DCM twice times after cooled to the room temperature. The combined organic layer was then wash with brine, dried over Na₂SO₄, filtrated, concentrated *in vacuo*. The crude mixture was purified by the flash

chromatography (PE/EA) to yield the corresponding product. The characterization data of substituted indolines were listed as follows.


3.4. General procedure A: the synthesis of compound 3a-3y:



Scheme S5. General procedure for the AAS reaction

At room temperature, to an oven-dried Schlenk tube charged with stir bar, $[\text{Ir}(\text{COD})\text{Cl}]_2$ (0.004 mmol, 2 mol%) and $(R)\text{-L1}$ (0.016 mmol, 8 mol%) refilled with argon two times. Redistilled CH_3CN (0.8 mL, 0.25 M) was added via syringe and the combined mixture was stirred for 30 min. After complexation, the organic heterogeneous solution was followed by the addition of indoline (0.2 mmol, 1.0 equiv), allylic alcohol (0.5 mmol, 2.5 equiv) and diphenyl phosphate (0.04 mmol, 20 mol%) sequentially. The reaction was stirred for additional 8~36 h. After completion, the mixture was directly concentrated *in vacuo*, and the residue was purified by silica gel column chromatography (PE/EA) rapidly to afford the desired compounds. The characterization data of C5-substituted indolines were listed as follows.

3.5. General procedure B: the synthesis of compound 4a-4h:



Scheme S6. General procedure for the AAS/oxidation reaction


At room temperature, to an oven-dried Schlenk tube charged with stir bar, $[\text{Ir}(\text{COD})\text{Cl}]_2$ (0.004 mmol, 2 mol%) and $(R)\text{-L1}$ (0.016 mmol, 8 mol%) refilled with argon two times. Redistilled CH_3CN (0.8 mL, 0.25 M) was added via syringe and the combined mixture was stirred for 30 min. After complexation, the organic heterogeneous solution was followed by the addition of indoline (0.2

mmol, 1.0 equiv), allylic alcohol (0.3 mmol, 1.5 equiv) and diphenyl phosphate (0.04 mmol, 20 mol%) sequentially. The reaction was stirred for additional 18~36 h. After completion, the mixture was added trimethylamine (30 mol%), CH₃CN (1 mL) and activated MnO₂ (5~10 equiv) and stirred for 6~12 h. The mixture was filtrated with celite and the filtrate was concentrated *in vacuo*. The residue was purified by silica gel column chromatography (PE/EA) rapidly to afford the desired compounds. The characterization data of C5-substituted indoles were reported as follows.

3.6 Stereodivergent synthesis of diallylated indoles

Then, a second iridium catalyzed AAS reaction was carried out by using **4a** and **2a**, the desired diallylated product **9a** was obtained in 85% yield and >20:1 *dr* without any erosion of the enantioselectivity. Recently, the stereodivergent synthetic route to access all stereoisomers of chiral compounds has gained much attention, since it would significantly enhance the efficiency for the chiral compound library design and diversity-oriented synthesis of natural product analogues and drug discovery.⁴ Thus, the enantiomeric isomers **4a** and **ent-4a** were applied to the second AAS reaction for the stereodivergent synthesis of diallylated products. It could be seen that all four stereoisomers **9a-9d** were afforded in 83-85% yields in >20:1 *dr*, and the *ee* values were all >99%.

(Scheme 4)




Scheme S5. Enantiodivergent synthesis of compound 9a-d

3.7 Deca-mmol scale preparation for a key chiral intermediate.

5-Indolyl aryl propylamines, which exhibited good activities for inhibition of Dopamine Transporter (DAT), were discovered and used as monoamine reuptake inhibitors and have attracted the attention of the scientific community.⁵ To test the reliability of our method, we applied


it in the rapid asymmetric construction of a key indole intermediate **10** for the synthesis of chiral 3-amino-1-arylpropyl indoles. Firstly, the allylation/oxidation reaction of *N*-benzyl-2-methylindoline (**1f**) with **2a** provided **4f** in 73% yield with >99% ee; secondly, **4f** was converted to **10** by a 9-BBN mediated hydroboration oxidation reaction, which could be further converted to **11** by a tosylation reaction in high yield and ee, which could be further converted to the chiral biogenic monoamine reuptake inhibitor **12** by following the literature. (Scheme 5)⁶



Scheme S6. Deca-mmol scale preparation for a key chiral intermediate. Conditions: a) standard condition; b) 9-BBN, then $\text{NaBO}_3 \cdot 4\text{H}_2\text{O}$, 0 °C to rt.; c) TsCl , DMAP, TEA, DCM. 9-BBN = 9-borabicyclo[3.3.1]nonane.


IV Characterization of products:

1-methylindoline (1b)^{3a}




Brown oil, 59.2 mg, yield (89%); ¹H NMR (500 MHz, CDCl₃) δ 7.10 – 7.03 (m, 2H), 6.70 – 6.63 (m, 1H), 6.50 – 6.46 (m, 1H), 3.28 (t, *J* = 8.1 Hz, 2H), 2.93 (t, *J* = 8.1 Hz, 2H), 2.75 (s, 3H). ¹³C NMR (125 MHz, CDCl₃) δ 153.5, 130.3, 127.4, 124.3, 117.8, 107.3, 56.2, 36.3, 28.8.

1-(4-methoxybenzyl)indoline (1c)^{3b}



White solid, 105.1 mg, yield (88%); ¹H NMR (500 MHz, CDCl₃) δ 7.30 – 7.26 (m, 3H), 7.11 – 7.03 (m, 2H), 6.90 – 6.85 (m, 2H), 6.67 – 6.64 (m, 1H), 6.54 – 6.50 (m, 1H), 4.19 (s, 2H), 3.81 (s, 3H), 3.27 (t, *J* = 8.3 Hz, 2H), 2.95 (t, *J* = 8.3 Hz, 2H). ¹³C NMR (125 MHz, CDCl₃) δ 158.8, 152.6, 130.4, 130.1, 129.2, 127.3, 124.5, 117.6, 113.9, 107.1, 55.3, 53.4, 53.0, 28.5.


1-benzyl-2,3-dimethylindoline (1d)^{3a}



Colorless oil, 80.6 mg, yield (68%); ¹H NMR (400 MHz, CDCl₃) δ 7.35 – 7.27 (m, 2H), 7.27 – 7.23 (m, 1H), 7.23 – 7.13 (m, 1H), 7.04 – 6.92 (m, 2H), 6.69 – 6.60 (m, 1H), 6.35 – 6.23 (m, 1H), 4.31 (dd, *J* = 29.2, 16.0 Hz, 1H), 4.09 (dd, *J* = 24.7, 16.0 Hz, 1H), 3.65 (dq, *J* = 13.3, 6.6 Hz, 1H, minor),


3.25 – 3.06 (m, 1H), 2.82 (dq, $J = 13.7, 6.8$ Hz, 1H, major), 1.26 (dd, $J = 8.9, 6.5$ Hz, 4H), 1.11 (dd, $J = 18.3, 6.8$ Hz, 2H). ^{13}C NMR (125 MHz, CDCl_3) δ 152.6, 151.8, 139.6, 139.5, 135.1, 134.0, 128.8, 128.7, 127.8, 127.7, 127.6, 127.2, 123.7, 123.0, 117.9, 117.9, 107.3, 107.2, 69.3, 63.1, 51.8, 50.4, 43.9, 39.4, 18.7, 17.5, 15.1, 13.2.

1-benzyl-2-methylindoline (1f)^{3a}




Yellowish oil, 91.4 mg, yield (82%); ^1H NMR (500 MHz, CDCl_3) δ 7.37 – 7.33 (m, 2H), 7.32 – 7.25 (m, 2H), 7.25 – 7.20 (m, 1H), 7.06 – 7.02 (m, 1H), 6.99 – 6.94 (m, 1H), 6.64 – 6.58 (m, 1H), 6.33 – 6.28 (m, 1H), 4.34 (d, $J = 16.1$ Hz, 1H), 4.17 (d, $J = 16.1$ Hz, 1H), 3.71 (tq, $J = 9.2, 6.1$ Hz, 1H), 3.14 (dd, $J = 15.5, 8.6$ Hz, 1H), 2.66 (dd, $J = 15.5, 9.5$ Hz, 1H), 1.28 (d, $J = 6.1$ Hz, 3H). ^{13}C NMR (125 MHz, CDCl_3) δ 152.8, 139.4, 128.9, 128.5, 127.5, 127.4, 127.0, 124.2, 117.5, 106.9, 60.7, 51.2, 37.5, 19.8.

1-benzyl-3-methylindoline (1g)^{3c}




Reddish oil, 79.1 mg, yield (72%); ^1H NMR (500 MHz, CDCl_3) δ 7.36 – 7.28 (m, 4H), 7.26 – 7.20 (m, 1H), 7.08 – 7.01 (m, 2H), 6.68 (m, 1H), 6.49 (m, 1H), 4.33 (d, $J = 14.8$ Hz, 1H), 4.08 (d, $J = 14.8$ Hz, 1H), 3.47 (t, $J = 8.6$ Hz, 1H), 3.31 – 3.22 (m, 1H), 2.80 (t, $J = 8.5$ Hz, 1H), 1.28 (d, $J = 6.8$ Hz, 3H). ^{13}C NMR (125 MHz, CDCl_3) δ 152.3, 138.7, 135.2, 128.6, 128.0, 127.6, 127.2, 123.3, 117.9, 107.2, 61.8, 53.6, 35.3, 18.8.

1-benzyl-4-methylindoline (1h)^{3c}




Reddish oil, 69.1 mg, yield (62%); ^1H NMR (500 MHz, CDCl_3) δ 7.36 – 7.28 (m, 4H), 7.27 – 7.23 (m, 1H), 6.99 – 6.93 (m, 1H), 6.53 – 6.47 (m, 1H), 6.37 – 6.33 (m, 1H), 4.24 – 4.20 (s, 2H), 3.30 (t, J = 8.4 Hz, 2H), 2.87 (t, J = 8.3 Hz, 2H), 2.19 (s, 3H). ^{13}C NMR (125 MHz, CDCl_3) δ 152.4, 138.7, 134.1, 128.6, 128.6, 128.0, 127.5, 127.2, 119.2, 104.7, 53.9, 53.4, 27.3, 18.7.

1-benzyl-2-phenylindoline (1i)^{3c}



White solid, 92.6 mg, yield (65%); ^1H NMR (500 MHz, CDCl_3) δ 7.48 – 7.37 (m, 2H), 7.36 – 7.26 (m, 2H), 7.26 – 7.15 (m, 6H), 7.10 – 6.97 (m, 2H), 6.73 – 6.68 (m, 1H), 6.43 – 6.25 (m, 1H), 4.62 (t, J = 9.5 Hz, 1H), 4.36 (d, J = 15.8 Hz, 1H), 3.94 (d, J = 15.8 Hz, 1H), 3.37 (dd, J = 15.4, 9.1 Hz, 1H), 3.01 (dd, J = 15.1, 10.6 Hz, 1H). ^{13}C NMR (125 MHz, CDCl_3) δ 152.5, 142.6, 138.4, 128.7, 128.5, 127.8, 127.7, 127.6, 126.9, 124.2, 118.0, 107.5, 77.4, 77.1, 76.9, 69.4, 51.0, 39.6.


1-benzyl-6-methylindoline (1j)



Colorless oil, 73.6 mg, yield (66%); ^1H NMR (500 MHz, CDCl_3) δ 7.38 – 7.30 (m, 4H), 7.29 – 7.24 (m, 1H), 7.00 – 6.95 (m, 1H), 6.51 – 6.47 (m, 1H), 6.36 – 6.33 (m, 1H), 4.23 (s, 2H), 3.28 (t, J = 8.3 Hz, 2H), 2.92 (t, J = 8.2 Hz, 2H), 2.27 (s, 3H). ^{13}C NMR (125 MHz, CDCl_3) δ 151.8, 137.6, 136.1, 127.4, 126.9, 126.0, 126.0, 123.2, 117.3, 106.9, 52.8, 52.6, 27.2, 20.7.


HRMS (ESI) m/z: [M + H]⁺ Calcd for C₁₆H₁₇N 224.1434; Found 224.1441.

4-benzyl-1,2,3,3a,4,8b-hexahydrocyclopenta[b]indole (1k)^{3d}




Colorless oil, 97.1 mg, yield (78%); ¹H NMR (500 MHz, CDCl₃) δ 7.29 – 7.26 (m, 4H), 7.24 – 7.19 (m, 1H), 7.03 – 6.99 (m, 1H), 6.97 – 6.92 (m, 1H), 6.60 – 6.53 (m, 1H), 6.24 – 6.18 (m, 1H), 4.39 (d, *J* = 16.2 Hz, 1H), 4.27 (d, *J* = 16.2 Hz, 1H), 4.21 – 4.16 (m, 1H), 3.73 (td, *J* = 9.0, 2.7 Hz, 1H), 2.01 – 1.91 (m, 1H), 1.84 – 1.75 (m, 2H), 1.66 – 1.51 (m, 3H). ¹³C NMR (125 MHz, CDCl₃) δ 152.4, 139.3, 133.6, 128.6, 127.6, 127.3, 126.9, 124.2, 116.7, 105.4, 69.9, 51.2, 45.9, 35.2, 33.3, 24.7.

1-benzyl-1,2,3,4-tetrahydroquinoline (1l)^{3d}



Pink solid, 98.1 mg, yield (88%); ¹H NMR (500 MHz, CDCl₃) δ 7.32 – 7.26 (m, 2H), 7.26 – 7.18 (m, 3H), 6.98 – 6.92 (m, 2H), 6.58 – 6.53 (m, 1H), 6.50 – 6.45 (m, 1H), 4.45 (s, 2H), 3.33 (m, 2H), 2.79 (t, *J* = 6.3 Hz, 2H), 2.03 – 1.94 (m, 2H). ¹³C NMR (125 MHz, CDCl₃) δ 145.7, 139.1, 129.1, 128.7, 127.3, 126.9, 126.7, 122.3, 116.0, 111.1, 55.3, 50.0, 28.4, 22.5.


1,4-dibenzyl-1,2,3,4-tetrahydroquinoxaline (1m)



White solid, 124.0 mg, yield (79%); ^1H NMR (500 MHz, CDCl_3) δ 7.27 – 7.24 (m, 7H), 7.21 – 7.15 (m, 3H), 6.55 – 6.47 (m, 4H), 4.38 (s, 4H), 3.33 (s, 4H). ^{13}C NMR (125 MHz, CDCl_3) δ 138.6, 135.8, 128.6, 127.2, 126.9, 118.1, 111.5, 55.6, 47.9.


HRMS (ESI) m/z: [M + H]⁺ Calcd for $\text{C}_{22}\text{H}_{22}\text{N}_2$ 315.1856; Found 315.1857.

4-benzyl-3,4-dihydro-2H-benzo[b][1,4]oxazine (1n)^{3d}




Brown solid, 75.4 mg, yield (67%); ^1H NMR (500 MHz, CDCl_3) δ 7.36 – 7.22 (m, 5H), 6.85 – 6.73 (m, 2H), 6.70 – 6.56 (m, 2H), 4.43 (s, 2H), 4.28 – 4.23 (m, 2H), 3.39 – 3.29 (m, 2H). ^{13}C NMR (125 MHz, CDCl_3) δ 144.0, 138.2, 135.7, 128.7, 127.2, 127.2, 121.7, 117.9, 116.4, 112.6, 64.7, 55.0, 47.4.

1-benzyl-1,2,3,4-tetrahydrobenzo[h]quinoline (1o)^{3d}




Ivory oil, 102.7 mg, yield (76%); ^1H NMR (500 MHz, CDCl_3) δ 8.16 – 8.12 (m, 1H), 7.78 – 7.74 (m, 1H), 7.65 – 7.60 (m, 2H), 7.47 – 7.40 (m, 3H), 7.39 – 7.31 (m, 3H), 7.19 – 7.14 (m, 1H), 4.34 (s, 2H), 3.18 – 3.13 (m, 2H), 2.94 (t, $J = 6.7$ Hz, 2H), 1.92 – 1.85 (m, 2H). ^{13}C NMR (125 MHz, CDCl_3) δ 144.2, 139.8, 133.5, 128.9, 128.7, 128.4, 128.2, 127.4, 127.0, 125.3, 125.3, 125.0, 122.9, 122.1, 59.1, 46.9, 28.0, 16.5.

1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinoline (1p)^{3d}



Yellowish oil, 49.3 mg, yield (62%); ^1H NMR (500 MHz, CDCl_3) δ 6.95 – 6.91 (m, 1H), 6.84 – 6.78 (m, 1H), 6.64 – 6.58 (m, 1H), 3.24 (t, J = 7.8 Hz, 2H), 2.99 – 2.95 (m, 2H), 2.90 (t, J = 7.8 Hz, 2H), 2.69 (t, J = 6.6 Hz, 2H), 2.12 – 2.06 (m, 2H). ^{13}C NMR (125 MHz, CDCl_3) δ 150.0, 128.8, 126.3, 121.9, 119.6, 118.6, 55.3, 47.5, 28.8, 24.0, 23.3.

(S)-1-benzyl-5-(1-(3-methoxyphenyl)allyl)indoline (3a)



Yellowish oil, 66.0 mg, yield (93%); $[\alpha]_D^{20} = -30.3$ (c 1.25, CHCl_3);


^1H NMR (500 MHz, CDCl_3) δ 7.38 – 7.30 (m, 4H), 7.28 – 7.24 (m, 1H), 7.23 – 7.17 (m, 1H), 6.94 – 6.88 (m, 1H), 6.87 – 6.85 (m, 1H), 6.83 – 6.72 (m, 3H), 6.45 – 6.41 (m, 1H), 6.30 – 6.22 (m, 1H), 5.19 – 5.13 (m, 1H), 5.03 – 4.96 (m, 1H), 4.61 – 4.56 (m, 1H), 4.21 (s, 2H), 3.77 (s, 3H), 3.28 (t, J = 8.3 Hz, 2H), 2.91 (t, J = 8.2 Hz, 2H).

^{13}C NMR (125 MHz, CDCl_3) δ 159.6, 151.2, 145.8, 141.2, 138.6, 132.6, 130.4, 129.2, 128.5, 128.0, 127.3, 127.1, 124.8, 121.1, 115.7, 114.6, 111.2, 106.8, 55.2, 54.6, 54.0, 53.9, 28.6.

>99% ee as determined by HPLC (OD-H, *i*-PrOH /*n*-hexane = 1/99, flow rate = 0.5 mL/min, l = 254 nm) t_R = 19.1 min (major), 18.2 min (minor).

HRMS (ESI) m/z: [M + H]⁺ Calcd for C₂₅H₂₆NO 356.2009; Found 356.2009.

(S)-5-(1-(3-methoxyphenyl)allyl)-1-methylindoline (3b)



Yellowish oil, 35.7 mg, yield (64%); $[\alpha]_D^{20} = +5.4$ (c 1.25, CHCl_3);


^1H NMR (500 MHz, CDCl_3) δ 7.23 – 7.17 (m, 1H), 6.93 – 6.87 (m, 2H), 6.82 – 6.77 (m, 1H), 6.77 – 6.71 (m, 2H), 6.43 – 6.39 (m, 1H), 6.30 – 6.22 (m, 1H), 5.19 – 5.14 (m, 1H), 5.02 – 4.95 (m, 1H), 4.61 – 4.56 (m, 1H), 3.77 (s, 3H), 3.26 (t, $J = 8.1$ Hz, 2H), 2.88 (t, $J = 8.1$ Hz, 2H), 2.73 (s, 3H).

^{13}C NMR (125 MHz, CDCl_3) δ 158.5, 151.0, 144.8, 140.2, 131.6, 129.6, 128.2, 126.3, 123.5, 120.0, 114.6, 113.5, 110.2, 106.0, 55.3, 54.1, 53.5, 35.4, 27.7.

>99% ee as determined by HPLC (AD-H, *i*-PrOH /*n*-hexane = 5/95, flow rate = 1.0 mL/min, $l = 254$ nm) $t_R = 5.1$ min (major), 4.6 min (minor).

HRMS (ESI) m/z: [M + H]⁺ Calcd for $\text{C}_{19}\text{H}_{22}\text{NO}$ 280.1696; Found 280.1698.

(S)-1-(4-methoxybenzyl)-5-(1-(3-methoxyphenyl)allyl)indoline (3c)



Yellowish oil, 63.3 mg, yield (82%); $[\alpha]_D^{20} = +4.5$ (c 1.25, CHCl_3);


^1H NMR (500 MHz, CDCl_3) δ 7.30 – 7.25 (m, 2H), 7.24 – 7.17 (m, 1H), 6.93 – 6.88 (m, 1H), 6.88 – 6.84 (m, 3H), 6.81 – 6.71 (m, 3H), 6.46 – 6.42 (m, 1H), 6.30 – 8.22 (m, 1H), 5.18 – 5.14 (m, 1H), 5.03 – 4.95 (m, 1H), 4.60 – 4.55 (m, 1H), 4.14 (s, 2H), 3.77 (d, $J = 13.5$ Hz, 6H), 3.23 (t, $J = 8.2$ Hz, 2H), 2.88 (t, $J = 8.2$ Hz, 2H).

^{13}C NMR (125 MHz, CDCl_3) δ 159.6, 158.8, 151.3, 145.9, 141.3, 132.6, 130.6, 130.5, 129.2, 129.2, 127.3, 124.8, 121.1, 115.7, 114.6, 113.9, 111.2, 106.9, 55.3, 55.2, 54.6, 53.8, 53.4, 28.6.

>99% ee as determined by HPLC (OD-H, *i*-PrOH /*n*-hexane = 5/95, flow rate = 1.0 mL/min, $l = 254$ nm) $t_R = 10.1$ min (major), 8.9 min (minor).

HRMS (ESI) m/z: [M + H]⁺ Calcd for C₂₆H₂₈NO₂ 386.2115; Found 386.2110.

(S)-1-benzyl-5-(1-(2-methoxyphenyl)allyl)indoline (3d)



Yellowish oil, 55.4 mg, yield (78%); $[\alpha]_D^{20} = +229.3$ (c 1.25, CHCl₃);


¹H NMR (500 MHz, CDCl₃) δ 7.38 – 7.30 (m, 4H), 7.28 – 7.24 (m, 1H), 7.20 – 7.15 (m, 1H), 7.14 – 7.08 (m, 1H), 6.95 – 6.82 (m, 4H), 6.45 – 6.37 (m, 1H), 6.33 – 6.23 (m, 1H), 5.17 – 5.12 (m, 1H), 5.11 – 5.05 (m, 1H), 4.93 – 4.85 (m, 1H), 4.19 (s, 2H), 3.78 (s, 3H), 3.28 (t, *J* = 8.3 Hz, 2H), 2.91 (t, *J* = 8.2 Hz, 2H).

¹³C NMR (125 MHz, CDCl₃) δ 156.9, 151.0, 141.3, 138.7, 132.6, 132.5, 130.1, 129.4, 128.5, 128.0, 127.4, 127.2, 127.1, 125.0, 120.5, 115.2, 110.8, 106.8, 55.7, 54.2, 54.0, 46.8, 28.6.

99% *ee* as determined by HPLC (OD-H, *i*-PrOH /*n*-hexane = 1/99, flow rate = 0.5 mL/min, λ = 254 nm) t_R = 22.5 min (major), 21.6 min (minor).

HRMS (ESI) m/z: [M + H]⁺ Calcd for C₂₅H₂₆NO 356.2009; Found 356.2015.

(R)-1-benzyl-5-(1-(4-methoxyphenyl)allyl)indoline (3e)



Yellowish oil, 41.9 mg, yield (59%); $[\alpha]_D^{20} = +2.8$ (c 1.25, CHCl₃);


¹H NMR (500 MHz, CDCl₃) δ 7.37 – 7.28 (m, 4H), 7.27 – 7.22 (m, 1H), 7.14 – 7.07 (m, 2H), 6.92 – 6.87 (m, 1H), 6.86 – 6.80 (m, 3H), 6.45 – 6.40 (m, 1H), 6.30 – 6.20 (m, 1H), 5.16 – 5.11 (m, 1H), 4.99 – 4.93 (m, 1H), 4.60 – 4.55 (m, 1H), 4.20 (s, 2H), 3.77 (s, 3H), 3.27 (t, *J* = 8.3 Hz, 2H), 2.90 (t, *J* = 8.2 Hz, 2H).

^{13}C NMR (125 MHz, CDCl_3) δ 158.0, 151.3, 141.8, 138.7, 136.3, 133.2, 130.4, 129.50, 128.5, 128.0, 127.3, 127.1, 124.8, 115.4, 113.7, 106.8, 55.3, 54.1, 54.0, 53.7, 28.6.

91% *ee* as determined by HPLC (OD-H, *i*-PrOH /*n*-hexane = 1/99, flow rate = 0.5 mL/min, λ = 254 nm) t_R = 32.3 min (major), 30.7 min (minor).

HRMS (ESI) m/z: [M + H]⁺ Calcd for $\text{C}_{25}\text{H}_{26}\text{NO}$ 356.2009; Found 356.2001.

(R)-1-benzyl-5-(1-phenylallyl)indoline (3f)



Yellowish oil, 50.0 mg, yield (77%); $[\alpha]_D^{20} = +7.6$ (c 1.25, CHCl_3);


^1H NMR (500 MHz, CDCl_3) δ 7.36 – 7.23 (m, 7H), 7.21 – 7.16 (m, 3H), 6.93 – 6.88 (m, 1H), 6.87 – 6.84 (m, 1H), 6.45 – 6.40 (m, 1H), 6.33 – 6.23 (m, 1H), 5.20 – 5.13 (m, 1H), 5.02 – 4.94 (m, 1H), 4.65 – 4.57 (m, 1H), 4.20 (s, 2H), 3.27 (t, J = 8.3 Hz, 2H), 2.90 (t, J = 8.2 Hz, 2H).

^{13}C NMR (125 MHz, CDCl_3) δ 151.3, 144.3, 141.5, 138.7, 132.9, 130.4, 128.6, 128.5, 128.4, 128.0, 127.4, 127.1, 126.2, 124.9, 115.7, 106.9, 54.6, 54.1, 54.0, 28.6.

>99% *ee* as determined by HPLC (OD-H, *i*-PrOH /*n*-hexane = 1/99, flow rate = 1.0 mL/min, λ = 254 nm) t_R = 9.8 min (major), 10.5 min (minor).

HRMS (ESI) m/z: [M + H]⁺ Calcd for $\text{C}_{24}\text{H}_{24}\text{N}$ 326.1903; Found 326.1910.

(S)-1-benzyl-5-(1-(3-ethoxy-4-methylphenyl)allyl)indoline (3g)



Yellowish oil, 57.6 mg, yield (75%); $[\alpha]_D^{20} = +7.69$ (c 1.25, CHCl_3);


¹H NMR (500 MHz, CDCl₃) δ 7.39 – 7.29 (m, 4H), 7.28 – 7.21 (m, 1H), 6.93 – 6.87 (m, 1H), 6.92 – 6.83 (m, 1H), 6.83 – 6.77 (m, 1H), 6.76 – 6.68 (m, 2H), 6.47 – 6.40 (m, 1H), 6.30 – 6.19 (m, 1H), 5.10 – 5.13 (m, 1H), 5.03 – 4.95 (m, 1H), 4.58 – 4.52 (m, 1H), 4.20 (s, 2H), 4.04 (q, *J* = 7.0 Hz, 2H), 3.83 (s, 3H), 3.27 (t, *J* = 8.3 Hz, 2H), 2.91 (t, *J* = 8.2 Hz, 2H), 1.42 (t, *J* = 7.0 Hz, 3H).

¹³C NMR (125 MHz, CDCl₃) δ 151.2, 148.1, 147.7, 141.7, 138.6, 136.7, 133.0, 130.4, 128.5, 128.0, 127.3, 127.1, 124.8, 120.5, 115.4, 113.6, 111.4, 106.9, 64.3, 56.0, 54.1, 54.1, 53.9, 28.6, 14.9.

93% *ee* as determined by HPLC (AD-H, *i*-PrOH /*n*-hexane = 3/97, flow rate = 1.0 mL/min, *l* = 254 nm) t_R = 9.6 min (major), 10.3 min (minor).

HRMS (ESI) m/z: [M + H]⁺ Calcd for C₂₇H₃₀NO 384.2322; Found 384.2329.

(R)-1-benzyl-5-(1-(4-fluorophenyl)allyl)indoline (3h)



Yellowish oil, 59.0 mg, yield (86%); [α]_D²⁰ = +233.8 (c 1.25, CHCl₃);

¹H NMR (500 MHz, CDCl₃) δ 7.57 – 7.53 (m, 1H), 7.37 – 7.30 (m, 4H), 7.28 – 7.22 (m, 2H), 7.20 – 7.16 (m, 1H), 7.08 – 7.02 (m, 1H), 6.93 – 6.89 (m, 1H), 6.89 – 6.84 (m, 1H), 6.46 – 6.41 (m, 1H), 6.26 – 6.18 (m, 1H), 5.24 – 5.17 (m, 1H), 5.15 – 5.10 (m, 1H), 4.93 – 4.86 (m, 1H), 4.21 (s, 2H), 3.28 (t, *J* = 8.3 Hz, 2H), 2.92 (t, *J* = 8.2 Hz, 2H).


¹³C NMR (125 MHz, CDCl₃) δ 162.4 (C-F, *1J*_{C-F} = 242.7 Hz), 160.4 (C-F, *1J*_{C-F} = 242.7 Hz), 151.4, 141.3, 139.9, 139.8, 138.6, 132.6, 130.5, 130.0 (C-F, *3J*_{C-F} = 7.7 Hz), 130.0 (C-F, *3J*_{C-F} = 7.7 Hz), 128.5, 128.0, 127.4, 127.2, 124.8, 115.8, 115.1 (C-F, *2J*_{C-F} = 21.0 Hz), 115.1 (C-F, *2J*_{C-F} = 21.0 Hz), 106.9, 54.0, 53.9, 53.8, 28.6.

¹⁹F NMR (471 MHz, CDCl₃) δ -117.3.

>99% *ee* as determined by HPLC (OJ, *i*-PrOH /*n*-hexane = 1/99, flow rate = 1.0 mL/min, *l* = 254 nm) t_R = 12.8 min (major), 16.2 min (minor).

HRMS (ESI) m/z: [M + H]⁺ Calcd for C₂₄H₂₃NF 344.1809; Found 344.1804.

(R)-1-benzyl-5-(1-(4-chlorophenyl)allyl)indoline (3i)



Yellowish viscous oil, 62.6 mg, yield (87%); $[\alpha]_D^{20} = +2.5$ (c 1.25, CHCl₃);


¹H NMR (500 MHz, CDCl₃) δ 7.36 – 7.29 (m, 4H), 7.27 – 7.21 (m, 3H), 7.14 – 7.09 (m, 2H), 6.89 – 6.85 (m, 1H), 6.85 – 6.81 (m, 1H), 6.45 – 6.39 (m, 1H), 6.26 – 6.18 (m, 1H), 5.20 – 5.14 (m, 1H), 5.00 – 4.91 (m, 1H), 4.62 – 4.55 (m, 1H), 4.20 (s, 2H), 3.28 (t, *J* = 8.3 Hz, 2H), 2.90 (t, *J* = 8.3 Hz, 2H).

¹³C NMR (125 MHz, CDCl₃) δ 151.4, 142.7, 141.0, 138.6, 132.2, 131.9, 130.6, 130.0, 128.5, 128.4, 128.0, 127.4, 127.2, 124.8, 116.0, 106.9, 54.0, 53.9, 53.9, 28.6.

>99% *ee* as determined by HPLC (OJ, *i*-PrOH /*n*-hexane = 1/99, flow rate = 0.5 mL/min, *l* = 254 nm) t_R = 44.5 min (major), 26.2 min (minor).

HRMS (ESI) m/z: [M + H]⁺ Calcd for C₂₄H₂₃CIN 360.1514; Found 360.1518.

(R)-1-benzyl-5-(1-(4-bromophenyl)allyl)indoline (3j)



Yellowish solid, 64.6 mg, yield (80%); mp. = 77.1–78.9 °C; $[\alpha]_D^{20} = -35.6$ (c 1.25, CHCl₃);


¹H NMR (500 MHz, CDCl₃) δ 7.42 – 7.37 (m, 2H), 7.36 – 7.29 (m, 4H), 7.27 – 7.23 (m, 1H), 7.09 – 7.03 (m, 2H), 6.89 – 6.85 (m, 1H), 6.85 – 6.80 (m, 1H), 6.46 – 6.39 (m, 1H), 6.26 – 6.17 (m, 1H), 5.21 – 5.15 (m, 1H), 4.99 – 4.92 (m, 1H), 4.60 – 4.52 (m, 1H), 4.20 (s, 2H), 3.28 (t, *J* = 8.3 Hz, 2H), 2.91 (t, *J* = 8.3 Hz, 2H).

¹³C NMR (125 MHz, CDCl₃) δ 151.4, 143.2, 140.9, 138.5, 132.1, 131.4, 130.6, 130.4, 128.5, 128.0, 127.4, 127.2, 124.8, 120.0, 116.1, 106.9, 54.0, 53.9, 53.9, 28.6.

>99% ee as determined by HPLC (OD-H, *i*-PrOH /*n*-hexane = 2/98, flow rate = 1.0 mL/min, λ = 254 nm) t_R = 10.1 min (major), 10.9 min (minor).

HRMS (ESI) m/z: [M + H]⁺ Calcd for C₂₄H₂₃NBr 404.1008; Found 404.1000.

(R)-1-benzyl-5-(1-(4-iodophenyl)allyl)indoline (3k)



Yellowish solid, 74.0 mg, yield (82%); mp. = 78.0–79.1 °C; [α]_D²⁰ = +0.4 (c 1.25, CHCl₃);


¹H NMR (500 MHz, CDCl₃) δ 7.61 – 7.56 (m, 2H), 7.36 – 7.29 (m, 4H), 7.27 – 7.23 (m, 1H), 6.96 – 6.91 (m, 2H), 6.88 – 6.85 (m, 1H), 6.84 – 6.80 (m, 1H), 6.44 – 6.40 (m, 1H), 6.25 – 6.16 (m, 1H), 5.20 – 5.14 (m, 1H), 5.00 – 4.92 (m, 1H), 4.58 – 4.52 (m, 1H), 4.20 (s, 2H), 3.28 (t, *J* = 8.3 Hz, 2H), 2.90 (t, *J* = 8.3 Hz, 2H).

¹³C NMR (125 MHz, CDCl₃) δ 151.4, 143.9, 140.8, 138.5, 137.4, 132.1, 130.8, 130.6, 128.5, 128.0, 127.4, 127.2, 124.8, 116.1, 106.9, 91.5, 54.0, 54.0, 53.9, 28.6.

>99% ee as determined by HPLC (OD-H, *i*-PrOH /*n*-hexane = 1/99, flow rate = 0.5 mL/min, λ = 254 nm) t_R = 17.7 min (major), 19.4 min (minor).

HRMS (ESI) m/z: [M + H]⁺ Calcd for C₂₄H₂₃NI 452.0870; Found 452.0866.

(R)-5-(1-(4-iodophenyl)allyl)-1-(4-methoxybenzyl)indoline (3l)



Yellowish oil, 73.1 mg, yield (76%); $[\alpha]_D^{20} = -0.3$ (c 1.25, CHCl₃);


¹H NMR (500 MHz, CDCl₃) δ 7.61 – 7.56 (m, 2H), 7.63 – 7.24 (m, 2H), 6.97 – 6.91 (m, 2H), 6.88 – 6.80 (m, 4H), 6.46 – 6.42 (m, 1H), 6.25 – 6.16 (m, 1H), 5.20 – 5.15 (m, 1H), 4.98 – 4.93 (m, 1H), 4.57 – 4.52 (m, 1H), 4.14 (s, 2H), 3.79 (s, 3H), 3.25 (t, J = 8.3 Hz, 2H), 2.89 (t, J = 8.2 Hz, 2H).

¹³C NMR (125 MHz, CDCl₃) δ 158.8, 151.3, 143.9, 140.8, 137.3, 132.0, 130.7, 130.6, 130.4, 129.2, 127.3, 124.7, 116.1, 113.9, 106.9, 91.4, 55.3, 54.0, 53.7, 53.3, 28.5.

>99% ee as determined by HPLC (OD-H, *i*-PrOH /*n*-hexane = 0.8/99.2, flow rate = 1.0 mL/min, λ = 254 nm) t_R = 22.1 min (major), 24.3 min (minor).

HRMS (ESI) m/z: [M + H]⁺ Calcd for C₂₅H₂₅INO 482.0975; Found 482.0973.

(S)-1-benzyl-5-(1-(2-chlorophenyl)allyl)indoline (3m)



Yellowish oil, 36.0 mg, yield (50%); $[\alpha]_D^{20} = -5.4$ (c 1.25, CHCl₃);


¹H NMR (500 MHz, CDCl₃) δ 7.36 – 7.26 (m, 5H), 7.26 – 7.22 (m, 1H), 7.21 – 7.15 (m, 2H), 7.13 – 7.08 (m, 1H), 6.93 – 6.87 (m, 1H), 6.87 – 6.83 (m, 1H), 6.46 – 6.38 (m, 1H), 6.27 – 6.17 (m, 1H), 5.23 – 5.16 (m, 1H), 5.15 – 5.10 (m, 1H), 4.93 – 4.85 (m, 1H), 4.20 (s, 2H), 3.27 (t, J = 8.1 Hz, 2H), 2.90 (t, J = 8.2 Hz, 2H).

¹³C NMR (125 MHz, CDCl₃) δ 151.4, 141.5, 140.2, 138.6, 134.2, 131.2, 130.4, 130.2, 129.7, 128.5, 128.0, 127.7, 127.5, 127.2, 126.7, 125.1, 116.4, 106.8, 54.0, 53.9, 50.4, 28.6.

97% ee as determined by HPLC (OD-H, *i*-PrOH /*n*-hexane = 1/99, flow rate = 0.5 mL/min, λ = 254 nm) t_R = 19.7 min (major), 18.2 min (minor).

HRMS (ESI) m/z: [M + H]⁺ Calcd for C₂₄H₂₃ClN 360.1514; Found 360.1522.


(S)-1-benzyl-5-(1-(2-bromophenyl)allyl)indoline (3n)



Yellowish solid, 54.1 mg, yield (67%); mp. = 52.8–58.4 °C; $[\alpha]_D^{20} = +5.6$ (c 1.25, CHCl₃);
¹H NMR (500 MHz, CDCl₃) δ 7.37 – 7.30 (m, 4H), 7.28 – 7.23 (m, 1H), 7.17 – 7.11 (m, 2H), 6.99 – 6.93 (m, 2H), 6.90 – 6.86 (m, 1H), 6.85 – 6.81 (m, 1H), 6.45 – 6.40 (m, 1H), 6.28 – 6.19 (m, 1H), 5.19 – 5.14 (m, 1H), 4.98 – 4.92 (m, 1H), 4.62 – 4.57 (m, 1H), 4.20 (s, 2H), 3.28 (t, *J* = 8.3 Hz, 2H), 2.91 (t, *J* = 8.3 Hz, 2H).
¹³C NMR (125 MHz, CDCl₃) δ 151.3, 141.3, 139.8, 139.8, 138.6, 130.0, 129.9, 128.5, 128.0, 127.3, 127.2, 124.8, 115.8, 115.1, 115.0, 106.9, 54.0, 53.9, 53.8, 28.6.
>99% ee as determined by HPLC (OD-H, *i*-PrOH /*n*-hexane = 1/99, flow rate = 1.0 mL/min, λ = 254 nm) t_R = 8.4 min (major), 7.4 min (minor).

HRMS (ESI) m/z: [M + H]⁺ Calcd for C₂₄H₂₃BrN 404.1008; Found 404.1000.

(S)-5-(1-(3-chlorophenyl)allyl)-1-(4-methoxybenzyl)indoline (3o)




Yellowish oil, 47.6 mg, yield (61%); $[\alpha]_D^{20} = -3.0$ (c 1.25, CHCl₃);
¹H NMR (500 MHz, CDCl₃) δ 7.30 – 7.23 (m, 3H), 7.23 – 7.13 (m, 3H), 7.10 – 7.05 (m, 1H), 6.90 – 6.81 (m, 4H), 6.48 – 6.42 (m, 1H), 6.27 – 6.18 (m, 1H), 5.23 – 5.17 (m, 1H), 5.01 – 4.93 (m, 1H), 4.61 – 4.54 (m, 1H), 4.15 (s, 2H), 3.80 (d, *J* = 0.7 Hz, 3H), 3.26 (t, *J* = 8.1 Hz, 2H), 2.90 (t, *J* = 8.2 Hz, 2H).
¹³C NMR (125 MHz, CDCl₃) δ 158.8, 151.4, 146.3, 140.7, 134.1, 131.8, 130.6, 130.4, 129.5, 129.2, 128.6, 127.3, 126.8, 126.3, 124.7, 116.2, 113.9, 106.9, 55.3, 54.2, 53.7, 53.3, 28.5.

98% *ee* as determined by HPLC (OD-H, *i*-PrOH /*n*-hexane = 0.8/99.2, flow rate = 1.0 mL/min, λ = 254 nm) t_R = 13.1 min (major), 12.3 min (minor).

HRMS (ESI) m/z: [M + H]⁺ Calcd for C₂₅H₂₅CINO 390.1619; Found 390.1613.

methyl (*R*)-4-(1-(1-benzylindolin-5-yl)allyl)benzoate (3p)



Yellowish oil, 54.5 mg, yield (75%); [α]_D²⁰ = +0.3 (c 1.25, CHCl₃);


¹H NMR (500 MHz, CDCl₃) δ 7.99 – 7.93 (m, 2H), 7.37 – 7.29 (m, 4H), 7.29 – 7.21 (m, 3H), 6.90 – 6.86 (m, 1H), 6.86 – 6.82 (m, 1H), 6.45 – 6.40 (m, 1H), 6.30 – 6.20 (m, 1H), 5.22 – 5.17 (m, 1H), 5.00 – 4.94 (m, 1H), 4.68 – 4.64 (m, 1H), 4.21 (s, 2H), 3.88 (s, 3H), 3.28 (t, J = 8.3 Hz, 2H), 2.91 (t, J = 8.3 Hz, 2H).

¹³C NMR (125 MHz, CDCl₃) δ 167.2, 151.4, 149.6, 140.6, 138.5, 131.9, 130.6, 129.7, 128.6, 128.5, 128.1, 128.0, 127.4, 127.2, 124.8, 116.3, 106.9, 54.5, 53.9, 53.9, 52.0, 28.6.

>99% *ee* as determined by HPLC (AD-H, *i*-PrOH /*n*-hexane = 3/97, flow rate = 1.0 mL/min, λ = 254 nm) t_R = 10.2 min (major), 9.5 min (minor).

HRMS (ESI) m/z: [M + H]⁺ Calcd for C₂₆H₂₆NO₂ 384.1958; Found 384.1968.

(*R*)-1-benzyl-5-(1-(4-nitrophenyl)allyl)indoline (3q)



Brown oil, 35.5 mg, yield (48%); [α]_D²⁰ = -1.8 (c 1.25, CHCl₃);


¹H NMR (500 MHz, CDCl₃) δ 8.17 – 8.10 (m, 2H), 7.38 – 7.30 (m, 6H), 7.29 – 7.25 (m, 1H), 6.88 – 6.85 (m, 1H), 6.85 – 6.80 (m, 1H), 6.46 – 6.42 (m, 1H), 6.28 – 6.20 (m, 1H), 5.27 – 5.21 (m, 1H), 5.03 – 4.95 (m, 1H), 4.74 – 4.67 (m, 1H), 4.23 (s, 2H), 3.31 (t, *J* = 8.3 Hz, 2H), 2.93 (t, *J* = 8.3 Hz, 2H).

¹³C NMR (125 MHz, CDCl₃) δ 151.9, 151.6, 146.4, 139.9, 138.4, 131.0, 130.8, 129.4, 128.5, 127.9, 127.4, 127.2, 124.7, 123.6, 116.9, 106.9, 54.3, 53.8, 29.7, 28.5.

97% *ee* as determined by HPLC (OJ, *i*-PrOH /*n*-hexane = 10/90, flow rate = 0.5 mL/min, *l* = 254 nm) t_R = 50.5 min (major), 46.6 min (minor).

HRMS (ESI) m/z: [M + H]⁺ Calcd for C₂₄H₂₃N₂O₂ 371.1754; Found 371.1761.

(R)-1-benzyl-5-(1-(p-tolyl)allyl)indoline (3r)



Yellowish oil, 54.6 mg, yield (79%); [α]_D²⁰ = -102.8 (c 1.25, CHCl₃);


¹H NMR (500 MHz, CDCl₃) δ 7.37 – 7.29 (m, 4H), 7.27 – 7.20 (m, 1H), 7.12 – 7.06 (m, 4H), 6.93 – 6.88 (m, 1H), 6.87 – 6.84 (m, 1H), 6.46 – 6.37 (m, 1H), 6.30 – 6.20 (m, 1H), 5.17 – 5.12 (m, 1H), 5.00 – 4.94 (m, 1H), 4.62 – 4.54 (m, 1H), 4.20 (s, 2H), 3.26 (t, *J* = 8.3 Hz, 2H), 2.90 (t, *J* = 8.2 Hz, 2H), 2.30 (s, 3H).

¹³C NMR (125 MHz, CDCl₃) δ 151.2, 141.7, 141.2, 138.7, 135.6, 133.1, 130.4, 129.1, 128.5, 128.5, 128.0, 127.3, 127.1, 124.8, 115.4, 106.9, 54.2, 54.1, 54.0, 28.6, 21.1.

>99% *ee* as determined by HPLC (OJ, *i*-PrOH /*n*-hexane = 5/95, flow rate = 1.0 mL/min, *l* = 254 nm) t_R = 18.5 min (major), 16.2 min (minor).

HRMS (ESI) m/z: [M + H]⁺ Calcd for C₂₅H₂₆N 340.2060; Found 340.2063.

(R)-1-benzyl-5-(1-(4-isobutylphenyl)allyl)indoline (3s)



Yellowish oil, 53.5 mg, yield (70%); $[\alpha]_D^{20} = -456.8$ (c 1.25, CHCl₃);


¹H NMR (500 MHz, CDCl₃) δ 7.37 – 7.29 (m, 4H), 7.27 – 7.21 (m, 1H), 7.11 – 7.08 (m, 2H), 7.07 – 7.03 (m, 2H), 6.94 – 6.90 (m, 1H), 6.88 – 6.84 (m, 1H), 6.45 – 6.40 (m, 1H), 6.32 – 6.23 (m, 1H), 5.17 – 5.13 (m, 1H), 5.00 – 4.93 (m, 1H), 4.63 – 4.55 (m, 1H), 4.20 (s, 2H), 3.28 (t, *J* = 8.3 Hz, 2H), 2.90 (t, *J* = 8.3 Hz, 2H), 2.43 (d, *J* = 7.2 Hz, 2H), 1.90 – 1.77 (m, 1H), 0.89 (d, *J* = 6.6 Hz, 6H).

¹³C NMR (125 MHz, CDCl₃) δ 151.2, 141.7, 141.4, 139.4, 138.7, 133.1, 130.4, 129.1, 128.5, 128.2, 128.0, 127.4, 127.1, 124.9, 115.4, 106.9, 54.3, 54.1, 54.0, 45.1, 30.3, 28.6, 22.5.

>99% ee as determined by HPLC (OD-H, *i*-PrOH /*n*-hexane = 1/99, flow rate = 0.5 mL/min, λ = 254 nm) t_R = 13.6 min (major), 12.9 min (minor).

HRMS (ESI) m/z: [M + H]⁺ Calcd for C₂₈H₃₂N 382.2529; Found 382.2533.

(*R*)-5-((1,1'-biphenyl)-4-yl)allyl-1-benzylindoline (3t)



Yellowish viscous oil, 78.0 mg, yield (97%); mp. = 77.2–79.1 °C; $[\alpha]_D^{20} = +0.1$ (c 1.25, CHCl₃);


¹H NMR (500 MHz, CDCl₃) δ 7.60 – 7.54 (m, 2H), 7.54 – 7.49 (m, 2H), 7.44 – 7.39 (m, 2H), 7.38 – 7.29 (m, 5H), 7.29 – 7.23 (m, 3H), 6.98 – 6.93 (s, 1H), 6.92 – 6.88 (m, 1H), 6.47 – 6.42 (m, 1H), 6.35 – 6.26 (m, 1H), 5.23 – 5.17 (m, 1H), 5.06 – 4.98 (m, 1H), 4.69 – 4.61 (m, 1H), 4.22 (s, 2H), 3.29 (t, *J* = 8.3 Hz, 2H), 2.93 (t, *J* = 8.2 Hz, 2H).

¹³C NMR (125 MHz, CDCl₃) δ 151.2, 143.3, 141.3, 141.0, 139.0, 138.6, 132.7, 130.4, 128.9, 128.7, 128.5, 127.9, 127.3, 127.1, 127.0, 127.0, 124.8, 115.7, 106.8, 54.2, 54.0, 53.9, 28.6.

98% *ee* as determined by HPLC (AD-H, *i*-PrOH /*n*-hexane = 3/97, flow rate = 1.0 mL/min, λ = 254 nm) t_R = 5.6 min (major), 5.2 min (minor).

HRMS (ESI) m/z: [M + H]⁺ Calcd for C₃₀H₂₈N 402.2216; Found 402.2210.

(S)-1-benzyl-5-(1-(6-bromobenzo[d][1,3]dioxol-5-yl)allyl)indoline (3u)



Green oil, 87.8 mg, yield (98%); $[\alpha]_D^{20} = -13.5$ (c 1.25, CHCl₃);


¹H NMR (500 MHz, CDCl₃) δ 7.37 – 7.30 (m, 4H), 7.27 – 7.23 (m, 1H), 7.03 – 6.98 (m, 1H), 6.92 – 6.88 (m, 1H), 6.87 – 6.84 (m, 1H), 6.67 – 6.63 (m, 1H), 6.45 – 6.40 (m, 1H), 6.20 – 6.12 (m, 1H), 5.91 (dd, *J* = 7.3, 1.3 Hz, 2H), 5.22 – 5.17 (m, 1H), 5.18 – 5.03 (m, 1H), 4.93 – 4.86 (m, 1H), 4.21 (s, 2H), 3.28 (t, *J* = 8.3 Hz, 2H), 2.92 (t, *J* = 8.2 Hz, 2H).

¹³C NMR (125 MHz, CDCl₃) δ 151.4, 147.3, 146.6, 140.1, 138.6, 136.4, 131.3, 130.4, 128.5, 128.0, 127.5, 127.1, 125.0, 116.4, 115.0, 112.7, 110.0, 106.8, 101.6, 54.0, 53.9, 52.6, 28.6.

>99% *ee* as determined by HPLC (OD-H, *i*-PrOH /*n*-hexane = 5/95, flow rate = 1.0 mL/min, λ = 254 nm) t_R = 9.4 min (major), 16.4 min (minor).

HRMS (ESI) m/z: [M + H]⁺ Calcd for C₂₅H₂₃BrNO₂ 448.0907; Found 448.0911.

(S)-1-benzyl-5-(1-(thiophen-3-yl)allyl)indoline (3v)



Yellowish oil, 56.9 mg, yield (86%); $[\alpha]_D^{20} = +264.8$ (c 1.25, CHCl₃);


¹H NMR (500 MHz, CDCl₃) δ 7.38 – 7.30 (m, 4H), 7.28 – 7.22 (m, 2H), 6.94 – 6.91 (m, 2H), 6.91 – 6.87 (m, 2H), 6.46 – 6.41 (m, 1H), 6.28 – 6.19 (m, 1H), 5.16 – 5.12 (m, 1H), 5.05 – 4.99 (m, 1H), 4.65 – 4.61 (m, 1H), 4.21 (s, 2H), 3.29 (t, *J* = 8.3 Hz, 2H), 2.92 (t, *J* = 8.3 Hz, 2H).

¹³C NMR (125 MHz, CDCl₃) δ 151.3, 145.0, 141.1, 138.6, 132.5, 130.4, 128.5, 128.3, 127.9, 127.1, 127.1, 125.2, 124.5, 121.1, 115.1, 106.9, 54.0, 53.9, 50.4, 28.6.

99% *ee* as determined by HPLC (OJ, *i*-PrOH /*n*-hexane = 1/99, flow rate = 1.0 mL/min, λ = 254 nm) t_R = 39.5 min (major), 30.1 min (minor).

HRMS (ESI) m/z: [M + H]⁺ Calcd for C₂₂H₂₂NS 332.1467; Found 332.1457.

(S)-3-(1-(1-benzylindolin-5-yl)allyl)-1-tosyl-1H-indole (3w)



Green oil, 88.2 mg, yield (85%); [α]_D²⁰ = +13.2 (c 1.25, CHCl₃);


¹H NMR (500 MHz, CDCl₃) δ 7.97 – 7.92 (m, 1H), 7.74 – 7.69 (m, 2H), 7.37 – 7.28 (m, 5H), 7.28 – 7.22 (m, 3H), 7.20 – 7.16 (m, 2H), 7.14 – 7.09 (m, 1H), 6.90 – 6.87 (m, 1H), 6.85 – 6.81 (m, 1H), 6.42 – 6.38 (m, 1H), 6.27 – 6.19 (m, 1H), 5.18 – 5.13 (m, 1H), 5.01 – 4.94 (m, 1H), 4.73 – 4.68 (m, 1H), 4.21 (s, 2H), 3.28 (t, *J* = 8.3 Hz, 2H), 2.89 (td, *J* = 8.0, 3.4 Hz, 2H), 2.31 (s, 3H).

¹³C NMR (125 MHz, CDCl₃) δ 151.6, 144.7, 139.7, 138.6, 135.7, 135.3, 130.6, 130.5, 130.5, 129.8, 128.5, 128.0, 127.2, 126.8, 126.1, 124.6, 124.5, 124.1, 123.0, 120.7, 115.8, 113.8, 106.9, 54.0, 53.9, 46.1, 28.6, 21.6.

96% *ee* as determined by HPLC (OD-H, *i*-PrOH /*n*-hexane = 5/95, flow rate = 1.0 mL/min, λ = 254 nm) t_R = 15.7 min (major), 18.2 min (minor).

HRMS (ESI) m/z: [M + H]⁺ Calcd for C₃₃H₃₁N₂O₂S 519.2101; Found 519.2101.

(R)-1-benzyl-5-(1-(naphthalen-2-yl)allyl)indoline (3x)



Yellowish viscous oil, 70.7 mg, yield (94%); $[\alpha]_D^{20} = +6.4$ (c 1.25, CHCl₃);


¹H NMR (500 MHz, CDCl₃) δ 7.82 – 7.72 (m, 3H), 7.67 – 7.63 (m, 1H), 7.46 – 7.39 (m, 2H), 7.38 – 7.29 (m, 5H), 7.28 – 7.22 (m, 1H), 6.95 – 6.88 (m, 2H), 6.47 – 6.42 (m, 1H), 6.41 – 6.33 (m, 1H), 5.26 – 5.18 (m, 1H), 5.07 – 4.99 (m, 1H), 4.82 – 4.73 (m, 1H), 4.21 (s, 2H), 3.27 (t, *J* = 8.3 Hz, 2H), 2.90 (t, *J* = 8.2 Hz, 2H).

¹³C NMR (125 MHz, CDCl₃) δ 151.2, 141.6, 141.2, 138.6, 133.5, 132.6, 132.1, 130.4, 128.5, 127.9, 127.8, 127.8, 127.6, 127.5, 127.5, 127.1, 126.6, 125.8, 125.4, 124.9, 115.9, 106.8, 54.6, 54.0, 53.9, 28.5.

98% *ee* as determined by HPLC (OD-H, *i*-PrOH /*n*-hexane = 1/99, flow rate = 1.0 mL/min, λ = 254 nm) t_R = 44.6 min (major), 53.7 min (minor).

HRMS (ESI) m/z: [M + H]⁺ Calcd for C₂₈H₂₆N 376.2060; Found 376.2065.

4-((*R*)-1-(1-benzylindolin-5-yl)allyl)phenyl (*S*)-2-(4-isobutylphenyl)propanoate (3y)



Yellowish oil, 94.3 mg, yield (89%); $[\alpha]_D^{20} = -120.7$ (c 1.25, CHCl₃);

¹H NMR (500 MHz, CDCl₃) δ 7.36 – 7.22 (m, 7H), 7.16 – 7.10 (m, 4H), 6.93 – 6.88 (m, 2H), 6.87 – 6.84 (s, 1H), 6.84 – 6.80 (m, 1H), 6.45 – 6.40 (m, 1H), 6.26 – 6.17 (m, 1H), 5.17 – 5.13 (m, 1H),


4.98 – 4.92 (m, 1H), 4.63 – 4.55 (m, 1H), 4.20 (s, 2H), 3.91 (q, J = 7.1 Hz, 1H), 3.26 (t, J = 8.3 Hz, 2H), 2.89 (t, J = 8.2 Hz, 2H), 2.46 (d, J = 7.2 Hz, 2H), 1.90 – 1.81 (m, 1H), 1.58 (d, J = 7.2 Hz, 3H), 0.90 (d, J = 6.6 Hz, 6H).

^{13}C NMR (125 MHz, CDCl_3) δ 173.3, 151.3, 149.2, 141.5, 141.2, 140.8, 138.6, 137.3, 132.5, 130.4, 129.5, 129.4, 128.5, 128.0, 127.4, 127.3, 127.1, 124.8, 121.1, 115.8, 106.8, 54.0, 53.9, 53.9, 45.3, 45.1, 30.2, 28.6, 22.5, 18.6.

93% *ee*, >20/1 *dr* as determined by HPLC (AD-H, *i*-PrOH /*n*-hexane = 0.8/99.2, flow rate = 1.0 mL/min, λ = 254 nm) t_R = 31.1 min (major), 26.9 min (minor).

HRMS (ESI) m/z: [M + H]⁺ Calcd for $\text{C}_{37}\text{H}_{40}\text{NO}$ 529.7240; Found 529.7244.

(*R*)-1-benzyl-5-(1-phenylallyl)-1H-indole (4a)



White solid, 53.0 mg, yield (82%); mp. = 51.7–53.0 °C; $[\alpha]_D^{20} = +2.2$ (c 1.25, CHCl_3);

^1H NMR (500 MHz, CDCl_3) δ 7.47 – 7.45 (m, 1H), 7.29 – 7.21 (m, 7H), 7.20 – 7.16 (m, 2H), 7.11 – 7.07 (m, 3H), 7.01 – 6.97 (m, 1H), 6.49 – 6.46 (m, 1H), 6.41 – 6.33 (m, 1H), 5.26 (s, 2H), 5.21 – 5.18 (m, 1H), 5.02 – 4.97 (m, 1H), 4.84 – 4.80 (m, 1H).

^{13}C NMR (125 MHz, CDCl_3) δ 144.3, 141.6, 137.6, 135.2, 134.6, 128.8, 128.8, 128.7, 128.5, 128.3, 127.6, 126.9, 126.1, 123.0, 120.5, 115.8, 109.6, 101.7, 55.1, 50.2.

>99% *ee* as determined by HPLC (OD-H, *i*-PrOH /*n*-hexane = 0.8/99.2, flow rate = 1.0 mL/min, λ = 254 nm) t_R = 29.1 min (major), 21.7 min (minor).

HRMS (ESI) m/z: [M + H]⁺ Calcd for $\text{C}_{24}\text{H}_{22}\text{N}$ 324.1747; Found 324.1746.

(*R*)-1-benzyl-2-methyl-5-(1-phenylallyl)-1H-indole (4b)



Yellowish solid, 49.2 mg, yield (73%); mp. = 92.1–93.4 °C; $[\alpha]_D^{20} = 0.5$ (c 1.25, CHCl₃);


¹H NMR (500 MHz, CDCl₃) δ 7.39 – 7.35 (m, 1H), 7.28 – 7.16 (m, 8H), 7.12 – 7.08 (m, 1H), 6.98 – 6.95 (m, 2H), 6.94 – 6.89 (m, 1H), 6.42 – 6.33 (m, 1H), 6.27 – 6.24 (m, 1H), 5.24 (s, 2H), 5.21 – 5.16 (m, 1H), 5.02 – 4.96 (m, 1H), 4.83 – 4.79 (m, 1H), 2.25 (d, *J* = 5.2 Hz, 3H).

¹³C NMR (125 MHz, CDCl₃) δ 144.3, 141.6, 137.9, 136.9, 136.0, 134.5, 128.7, 128.7, 128.2, 128.2, 127.2, 126.0, 126.0, 121.9, 119.3, 115.6, 109.1, 100.4, 55.1, 46.5, 12.8.

>99% *ee* as determined by HPLC (OD-H, *i*-PrOH /*n*-hexane = 0.8/99.2, flow rate = 1.0 mL/min, λ = 254 nm) t_R = 16.0 min (major), 14.1 min (minor).

HRMS (ESI) m/z: [M + H]⁺ Calcd for C₂₅H₂₄N 338.1903; Found 338.1897.

(*R*)-1-benzyl-3-methyl-5-(1-phenylallyl)-1H-indole (4c)



Yellowish oil, 49.9 mg, yield (74%); $[\alpha]_D^{20} = -0.9$ (c 1.25, CHCl₃);


¹H NMR (500 MHz, CDCl₃) δ 7.42 – 7.39 (m, 1H), 7.29 – 7.21 (m, 7H), 7.18 – 7.14 (m, 2H), 7.14 – 7.08 (m, 2H), 7.00 – 6.96 (m, 1H), 6.87 – 6.84 (m, 1H), 6.43 – 6.35 (m, 1H), 5.23 – 5.18 (m, 1H), 5.22 – 5.20 (s, 1H), 5.04 – 5.98 (m, 1H), 4.86 – 4.82 (m, 1H), 2.29 (d, *J* = 0.8 Hz, 3H).

¹³C NMR (125 MHz, CDCl₃) δ 144.4, 141.7, 137.9, 135.5, 133.9, 129.0, 128.7, 128.7, 128.3, 127.5, 126.9, 126.1, 126.1, 122.8, 118.6, 115.8, 110.8, 109.4, 55.2, 49.9, 9.7.

>99% *ee* as determined by HPLC (OD-H, *i*-PrOH /*n*-hexane = 0.8/99.2, flow rate = 1.0 mL/min, λ = 254 nm) t_R = 19.6 min (major), 21.4 min (minor).

HRMS (ESI) m/z: [M + H]⁺ Calcd for C₂₅H₂₄N 338.1903; Found 338.1899.

(R)-1-benzyl-4-methyl-5-(1-phenylallyl)-1H-indole (4d)



Yellowish oil, 43.1 mg, yield (64%); $[\alpha]_D^{20} = -13.3$ (c 1.25, CHCl₃);

¹H NMR (500 MHz, CDCl₃) δ 7.31 – 7.24 (m, 5H), 7.19 – 7.11 (m, 5H), 7.11 – 7.07 (m, 2H), 6.99 – 6.95 (m, 1H), 6.57 – 6.53 (m, 1H), 6.38 – 6.30 (m, 1H), 5.26 (s, 2H), 5.22 – 5.18 (m, 1H), 5.11 – 5.06 (m, 1H), 4.92 – 4.85 (d, *J* = 7.2 Hz, 1H), 2.48 (s, 3H).

¹³C NMR (125 MHz, CDCl₃) δ 143.8, 141.3, 137.6, 134.9, 131.7, 129.4, 128.9, 128.8, 128.2, 128.1, 127.8, 127.6, 126.9, 125.9, 123.0, 115.8, 107.2, 100.5, 50.7, 50.2, 15.3.

>99% *ee* as determined by HPLC (AD-H, *i*-PrOH /*n*-hexane = 5/95, flow rate = 1.0 mL/min, λ = 254 nm) t_R = 6.8 min (major), 4.6 min (minor).

HRMS (ESI) m/z: [M + H]⁺ Calcd for C₂₅H₂₄N 338.1903; Found 338.1901.

(R)-1-benzyl-5-(1-(3-methoxyphenyl)allyl)-6-methyl-1H-indole (4e)



Orange oil, 63.1 mg, yield (86%); $[\alpha]_D^{20} = -13.3$ (c 1.25, CHCl₃);


¹H NMR (500 MHz, CDCl₃) δ 7.44 – 7.40 (m, 1H), 7.31 – 7.23 (m, 3H), 7.20 – 7.15 (m, 1H), 7.14 – 7.09 (m, 2H), 7.08 – 7.04 (m, 1H), 7.03 – 6.99 (m, 1H), 6.78 – 6.70 (m, 3H), 6.47 – 6.43 (m, 1H), 6.39 – 6.31 (m, 1H), 5.26 (s, 2H), 5.23 – 5.19 (m, 1H), 4.95 – 4.91 (m, 1H), 4.89 – 4.83 (m, 1H), 3.74 (s, 3H), 2.30 (s, 3H).

¹³C NMR (125 MHz, CDCl₃) δ 159.6, 145.0, 141.4, 137.8, 135.5, 133.1, 130.6, 129.1, 128.8, 127.6, 127.5, 126.9, 126.8, 121.6, 120.7, 115.9, 115.1, 111.0, 110.8, 101.5, 55.1, 51.4, 50.0, 20.7.

99% *ee* as determined by HPLC (OD-H, *i*-PrOH /*n*-hexane = 5/95, flow rate = 1.0 mL/min, λ = 254 nm) t_R = 30.4 min (major), 37.8 min (minor).

HRMS (ESI) m/z: [M + H]⁺ Calcd for C₂₆H₂₆NO 368.2009; Found 368.2008.

(R)-1-benzyl-2-phenyl-5-(1-phenylallyl)-1H-indole (4f)



Yellowish oil, 55.2 mg, yield (69%); [α]_D²⁰ = +0.3 (c 1.25, CHCl₃);


¹H NMR (500 MHz, CDCl₃) δ 7.48 – 7.46 (m, 1H), 7.43 – 7.40 (m, 2H), 7.39 – 7.33 (m, 3H), 7.30 – 7.18 (m, 8H), 7.12 – 7.08 (m, 1H), 7.06 – 7.01 (m, 1H), 7.00 – 6.95 (m, 1H), 6.60 – 6.55 (m, 1H), 6.43 – 6.34 (m, 1H), 5.32 (s, 2H), 5.24 – 5.18 (m, 1H), 5.05 – 4.98 (m, 1H), 4.86 – 4.82 (m, 1H).

¹³C NMR (125 MHz, CDCl₃) δ 144.2, 142.1, 141.5, 138.3, 136.9, 135.3, 132.7, 129.2, 128.7, 128.6, 128.4, 128.3, 128.0, 127.2, 126.1, 126.1, 123.2, 120.1, 115.8, 110.5, 102.3, 55.1, 47.84.

86% *ee* as determined by HPLC (OD-H, *i*-PrOH /*n*-hexane = 0.8/99.2, flow rate = 0.5 mL/min, λ = 254 nm) t_R = 18.0 min (major), 19.7 min (minor).

HRMS (ESI) m/z: [M + H]⁺ Calcd for C₃₀H₂₆N 400.2060; Found 400.2064.

(R)-1-benzyl-2,3-dimethyl-5-(1-phenylallyl)-1H-indole (4g)



Yellowish oil, 50.5 mg, yield (72%); [α]_D²⁰ = +2.9 (c 1.25, CHCl₃);


¹H NMR (500 MHz, CDCl₃) δ 7.37 – 7.32 (m, 1H), 7.27 – 7.16 (m, 8H), 7.12 – 7.08 (m, 1H), 7.00 – 6.95 (m, 2H), 6.93 – 6.89 (m, 1H), 6.44 – 6.35 (m, 1H), 5.24 (s, 2H), 5.22 – 5.18 (m, 1H), 5.03 – 4.98 (m, 1H), 4.86 – 4.82 (m, 1H), 2.25 (d, *J* = 5.2 Hz, 6H).

¹³C NMR (125 MHz, CDCl₃) δ 144.5, 141.7, 138.3, 135.2, 133.8, 132.7, 128.7, 128.6, 128.2, 127.1, 126.1, 126.00, 121.8, 117.6, 115.6, 108.7, 106.9, 55.2, 46.6, 10.2, 8.9.

99% *ee* as determined by HPLC (OD-H, *i*-PrOH /*n*-hexane = 5/95, flow rate = 0.5 mL/min, λ = 254 nm) t_R = 12.4 min (major), 13.1 min (minor).

HRMS (ESI) m/z: [M + H]⁺ Calcd for C₂₆H₂₆N 352.2060; Found 352.2066.

(S)-4-benzyl-7-(1-(3-methoxyphenyl)allyl)-1,2,3,4-tetrahydropenta[b]indole (4h)



Reddish oil, 56.7 mg, yield (72%); mp. = 79.5–80.0 °C; [α]_D²⁰ = -1.2 (c 1.25, CHCl₃);


¹H NMR (500 MHz, CDCl₃) δ 7.30 – 7.20 (m, 9H), 7.20 – 7.15 (m, 1H), 7.13 – 7.05 (m, 3H), 6.92 – 6.86 (m, 1H), 6.43 – 6.33 (m, 1H), 5.24 – 5.15 (m, 1H), 5.17 (s, 2H), 5.03 – 4.95 (m, 1H), 4.85 – 4.77 (m, 1H), 2.83 (d, *J* = 6.9 Hz, 1H), 2.73 (d, *J* = 6.7 Hz, 6H), 2.48 (m, 1H).

¹³C NMR (125 MHz, CDCl₃) δ 146.6, 144.5, 141.7, 140.0, 138.1, 134.2, 128.7, 128.6, 128.3, 127.4, 126.7, 126.0, 124.6, 121.3, 118.3, 118.2, 115.7, 109.8, 55.2, 48.4, 28.5, 25.2, 24.8.

96% *ee* as determined by HPLC (OD-H, *i*-PrOH /*n*-hexane = 0.8/99.2, flow rate = 1.0 mL/min, λ = 254 nm) t_R = 14.2 min (major), 16.0 min (minor).


HRMS (ESI) m/z: [M + H]⁺ Calcd for C₂₈H₂₈NO 394.2165; Found 394.2168.

(R)-1-benzyl-6-(1-phenylallyl)-1,2,3,4-tetrahydroquinoline (5a)



Light green solid, 38.6 mg, yield (57%); mp. = 61.7–62.9 °C; $[\alpha]_D^{20} = +3.8$ (c 1.25, CHCl₃);
¹H NMR (500 MHz, CDCl₃) δ 7.31 – 7.15 (m, 10H), 6.81 – 6.74 (m, 2H), 6.47 – 6.42 (m, 1H), 6.30 – 6.21 (m, 1H), 5.17 – 5.12 (m, 1H), 5.00 – 4.93 (m, 1H), 4.58 – 4.54 (m, 1H), 4.42 (s, 2H), 3.35 – 3.28 (m, 2H), 2.76 (t, *J* = 6.2 Hz, 2H), 2.02 – 1.94 (m, 2H).
¹³C NMR (125 MHz, CDCl₃) δ 144.2, 144.2, 141.5, 139.2, 130.6, 129.1, 128.6, 128.3, 127.1, 126.80, 126.7, 126.1, 122.2, 115.5, 111.0, 55.5, 54.3, 49.9, 28.3, 22.5.
98% *ee* as determined by HPLC (OD-H, *i*-PrOH /*n*-hexane = 3/97, flow rate = 1.0 mL/min, λ = 254 nm) t_R = 6.3 min (major), 5.9 min (minor).
HRMS (ESI) m/z: [M + H]⁺ Calcd for C₂₅H₂₆N 340.2060; Found 340.2058.


(R)-4-benzyl-7-(1-phenylallyl)-3,4-dihydro-2H-benzo[b][1,4]oxazine (5b)



Yellowish oil, 32.7 mg, yield (48%); $[\alpha]_D^{20} = +1.6$ (c 1.25, CHCl₃);
¹H NMR (500 MHz, CDCl₃) δ 7.35 – 7.25 (m, 7H), 7.21 – 7.16 (m, 3H), 6.67 – 6.64 (m, 1H), 6.62 – 6.57 (m, 2H), 6.30 – 6.20 (m, 1H), 5.18 – 5.14 (m, 1H), 5.03 – 4.95 (m, 1H), 4.59 – 4.55 (m, 1H), 4.39 (s, 2H), 4.25 (dd, *J* = 5.6, 3.3 Hz, 2H), 3.33 – 3.29 (m, 2H).
¹³C NMR (125 MHz, CDCl₃) δ 144.0, 143.8, 141.1, 138.3, 134.2, 133.2, 128.8, 128.6, 128.4, 127.3, 127.3, 126.3, 121.6, 116.6, 115.9, 112.6, 64.9, 55.3, 54.3, 47.4.
82% *ee* as determined by HPLC (AD-H, *i*-PrOH /*n*-hexane = 5/95, flow rate = 1.0 mL/min, λ = 254 nm) t_R = 5.5 min (major), 6.1 min (minor).

HRMS (ESI) m/z: [M + H]⁺ Calcd for C₂₄H₂₄NO 342.1852; Found 342.1856.

(R)-1,4-dibenzyl-6-(1-phenylallyl)-1,2,3,4-tetrahydroquinoxaline (5c)



Brown oil, 43.1 mg, yield (50%); $[\alpha]_D^{20} = +1.8$ (c 1.25, CHCl₃);


¹H NMR (500 MHz, CDCl₃) δ 7.33 – 7.22 (m, 6H), 7.25 – 7.19 (m, 6H), 7.15 – 7.08 (m, 3H), 6.51 – 6.46 (m, 1H), 6.43 – 6.37 (m, 2H), 6.23 – 6.13 (m, 1H), 5.09 – 5.05 (m, 1H), 4.94 – 4.83 (m, 1H), 4.51 – 4.42 (m, 1H), 4.39 (s, 2H), 4.35 (d, *J* = 2.9 Hz, 2H), 3.39 – 3.32 (m, 4H).

¹³C NMR (125 MHz, CDCl₃) δ 144.0, 141.3, 138.8, 138.6, 135.6, 134.4, 132.9, 128.6, 128.6, 128.5, 128.2, 127.4, 127.3, 127.0, 126.9, 126.0, 118.0, 115.4, 112.2, 111.4, 55.8, 55.6, 54.7, 48.0, 47.9.

98% *ee* as determined by HPLC (AD-H, *i*-PrOH /*n*-hexane = 5/95, flow rate = 1.0 mL/min, λ = 254 nm) t_R = 5.5 min (major), 4.8 min (minor).

HRMS (ESI) m/z: [M + H]⁺ Calcd for C₃₁H₃₁N₂ 431.2482; Found 431.2481.

(R)-1-benzyl-6-(1-(3-methoxyphenyl)allyl)-1,2,3,4-tetrahydronaphthalen-1-ylbenzylamine (5d)



Yellowish oil, 61.3 mg, yield (73%); $[\alpha]_D^{20} = -11.8$ (c 1.25, CHCl₃);


¹H NMR (500 MHz, CDCl₃) δ 8.21 – 8.16 (m, 1H), 7.94 – 7.89 (m, 1H), 7.64 – 7.59 (m, 2H), 7.46 – 7.41 (m, 2H), 7.35 – 7.29 (m, 3H), 7.22 – 7.18 (m, 1H), 7.03 (s, 1H), 6.85 – 6.72 (m, 3H), 6.44 – 6.36 (m, 1H), 5.39 – 5.33 (m, 1H), 5.28 – 5.24 (m, 1H), 4.98 – 4.91 (m, 1H), 4.32 (s, 2H), 3.76 (s, 3H), 3.19 – 3.12 (m, 2H), 2.90 (td, *J* = 6.6, 1.2 Hz, 2H), 1.94 – 1.85 (m, 2H).

¹³C NMR (125 MHz, CDCl₃) δ 159.6, 144.9, 143.4, 140.8, 139.8, 132.4, 131.6, 129.4, 129.3, 128.6, 128.5, 127.4, 127.0, 125.0, 24.9, 124.7, 124.6, 123.4, 121.4, 116.6, 115.1, 111.1, 59.2, 55.2, 50.6, 46.9, 28.0, 16.5.

>99% ee as determined by HPLC (OD-H, *i*-PrOH /*n*-hexane = 5/95, flow rate = 1.0 mL/min, 1 = 254 nm) t_R = 10.4 min (major), 5.3 min (minor).

HRMS (ESI) m/z: [M + H]⁺ Calcd for C₃₀H₃₀NO 420.2322; Found 420.2320.

(R)-8-(1-phenylallyl)-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinoline (5e)



Light green oil, 41.3 mg, yield (75%); [α]_D²⁰ = +1.3 (c 1.25, CHCl₃);


¹H NMR (500 MHz, CDCl₃) δ 7.31 – 7.24 (m, 2H), 7.24 – 7.15 (m, 3H), 6.78 – 6.72 (m, 1H), 6.70 – 6.62 (m, 1H), 6.32 – 6.22 (m, 1H), 5.19 – 5.12 (m, 1H), 5.03 – 4.93 (m, 1H), 4.65 – 4.55 (m, 1H), 3.22 (t, *J* = 7.6 Hz, 2H), 2.99 – 2.92 (m, 2H), 2.85 (t, *J* = 7.7 Hz, 2H), 2.64 (t, *J* = 6.5 Hz, 2H), 2.07 (dt, *J* = 11.4, 5.9 Hz, 2H).

¹³C NMR (125 MHz, CDCl₃) δ 148.6, 144.3, 141.6, 133.8, 129.0, 128.6, 128.3, 126.3, 126.0, 122.2, 119.3, 115.5, 55.4, 54.9, 47.6, 28.8, 24.0, 23.3.

>99% ee as determined by HPLC (OD-H, *i*-PrOH /*n*-hexane = 0.8/99.2, flow rate = 1.0 mL/min, 1 = 254 nm) t_R = 4.7 min (major), 7.4 min (minor).

HRMS (ESI) m/z: [M + H]⁺ Calcd for C₂₀H₂₂N 276.1747; Found 276.1752.

(R)-9-(1-phenylallyl)-2,3,6,7-tetrahydro-1H,5H-pyrido[3,2,1-ij]quinoline (5f)



Reddish oil, 31.2 mg, yield (54%); $[\alpha]_D^{20} = -5.3$ (c 1.25, CHCl₃);

¹H NMR (500 MHz, CDCl₃) δ 7.30 – 7.26 (m, 2H), 7.22 – 7.14 (m, 3H), 6.62 – 6.57 (m, 2H), 6.30 – 6.21 (m, 1H), 5.17 – 5.12 (m, 1H), 5.00 – 4.94 (m, 1H), 4.54 – 4.90 (m, 1H), 3.10 – 3.05 (m, 4H), 2.70 (t, *J* = 6.6 Hz, 4H), 1.98 – 1.90 (m, 4H).


¹³C NMR (125 MHz, CDCl₃) δ 144.2, 141.5, 141.5 130.5, 128.5, 128.2, 126.9, 126.0, 121.6, 115.3, 54.4, 50.1, 27.6, 22.2.

97% *ee* as determined by HPLC (OJ, *i*-PrOH /*n*-hexane = 5/95, flow rate = 1.0 mL/min, λ = 254 nm)
*t*_R = 7.5 min (major), 8.7 min (minor).

HRMS (ESI) m/z: [M + H]⁺ Calcd for C₂₁H₂₄N 290.1903; Found 290.1902.


V. Transformations of Compound 4a

4.1. Pd/C-catalyzed Hydrogenation of Compound 4a:



The synthetic protocol of substituted indolines were accorded to the relevant literature. In a glove box, a 10 mL oven-dried flask charged with stir bar, allyl indole (0.1 mmol, 1.0 equiv), 10% Pd/C (0.005 mmol, 5 mol%) and MeOH (2 mL). The organic mixture was reacted under the H₂ (1 atm) and then oil bath heated to reflux to stir for 12 h until the starting material was consumed completely detected by TLC. The solution was filtrated with celite and the filtrate was concentrated under the reduced pressure. The residue was purified by column chromatography to afford the desired compound **6** as a yellowish oil, affording 20.5 mg of **6** in 63% yield and 93% ee.

(*R*)-1-benzyl-5-(1-phenylpropyl)-1H-indole (**6**)



Yellowish oil, 20.5 mg, yield (63%); $[\alpha]_D^{20} = -0.7$ (c 1.25, CHCl₃);


¹H NMR (500 MHz, CDCl₃) δ 7.55 – 7.50 (m, 1H), 7.31 – 7.24 (m, 8H), 7.18 – 7.00 (m, 6H), 6.50 – 6.45 (m, 1H), 5.26 (s, 2H), 3.87 (t, *J* = 7.6 Hz, 1H), 2.15 – 2.09 (m, 2H), 0.91 (t, *J* = 7.2 Hz, 3H).

¹³C NMR (125 MHz, CDCl₃) δ 146.2, 137.6, 136.4, 135.0, 128.7, 128.7, 128.3, 128.2, 128.0, 127.6, 126.0, 125.7, 122.4, 119.6, 109.5, 101.5, 53.3, 50.1, 29.0, 13.0.

93% ee as determined by HPLC (OD-H, *i*-PrOH /*n*-hexane = 0.8/99.2, flow rate = 1.0 mL/min, λ = 254 nm) t_R = 23.0 min (major), 28.3 min (minor).


HRMS (ESI) m/z: [M + H]⁺ Calcd for C₂₄H₂₄N 326.1903; Found 326.1897.

4.2. Ru-catalyzed Olefin Metathesis of Compound 4a:



To an oven-dried flask charged with stir bar and Hoveyda-Grubbs II catalyst (0.0045 mmol, 4.5 mol%) carefully refilled with argon 3 times, then followed by anhydrous DCM (0.2 M), allyl indole (0.1 mmol, 1.0 equiv) and tert-butyl acylate (0.2 mmol, 2.0 equiv). The homogeneous solution was oil bath heated to reflux and stirred for 12 h. After completion, the solvent was removed under the reduced pressure and the residue was purified by flash chromatography to give the product **7** as a yellowish solid, affording 23.7 mg of **7** in 56% yield.

tert-butyl (*R,E*)-4-(1-benzyl-1H-indol-5-yl)-4-phenylbut-2-enoate (7)



Yellowish solid, 23.7 mg, yield (56%); mp. = 116.7–118.0 °C; $[\alpha]_D^{20} = +1.6$ (c 1.25, CHCl₃);


¹H NMR (500 MHz, CDCl₃) δ 7.45 – 7.43 (m, 1H), 7.42 – 7.35 (m, 1H), 7.28 – 7.16 (m, 9H), 7.14 – 7.10 (m, 3H), 6.98 – 6.94 (m, 1H), 6.51 – 6.46 (m, 1H), 5.70 – 5.63 (m, 1H), 5.29 (s, 2H), 4.97 – 4.90 (m, 1H), 1.46 (s, 9H).

¹³C NMR (125 MHz, CDCl₃) δ 166.1, 149.6, 142.7, 137.4, 135.3, 133.0, 128.9, 128.8, 128.7, 128.5, 127.7, 126.9, 126.6, 124.2, 122.8, 120.7, 109.9, 101.7, 80.3, 53.4, 50.2, 28.2.

>99% ee as determined by HPLC (OD-H, *i*-PrOH /*n*-hexane = 4/96, flow rate = 0.5 mL/min, λ = 254 nm) t_R = 46.3 min (major), 42.4 min (minor).


HRMS (ESI) m/z: [M + H]⁺ Calcd for C₂₉H₃₀NO₂ 424.2271; Found 424.2269.

.3. Vilsmeier-Haack Formylation of Compound 4a:



To an oven-dried flask charged with stir bar and allyl indole (0.1 mmol, 1.0 equiv) refilled with argon twice, followed by anhydrous DMF solvent (0.33mL). The system was cooled at 0°C atmosphere (ice-bath). 3.0 equivalent of POCl_3 was added to the reaction mixture dropwise over 5 min via syringe. Afterwards, the mixture was proceeded 30 min under the same condition, then removed from ice-bath and warmed to ambient temperature to stir for another 12 h. The mixture was quenched and washed with cool water (10 mL) and extracted with Et_2O ($3 \times 10 \text{ mL}$). The organic layer was separated, dried over anhydrous Na_2SO_4 , concentrated *in vacuo* and purified by the flash chromatography to give the product **8** as a yellowish oil, affording 27.0 mg of **8** in 77% yield.

(R)-1-benzyl-5-(1-phenylallyl)-1H-indole-3-carbaldehyde (8)



Yellowish oil, 27.0 mg, yield (77%); $[\alpha]_D^{20} = +1.5$ (c 1.25, CHCl_3);

$^1\text{H NMR}$ (500 MHz, CDCl_3) δ 9.96 (s, 1H), 8.25 – 8.20 (m, 1H), 7.70 – 7.64 (m, 1H), 7.36 – 7.31 (m, 3H), 7.29 – 7.15 (m, 8H), 7.13 – 7.08 (m, 1H), 6.42 – 6.34 (m, 1H), 5.30 (s, 2H), 5.25 – 5.20 (m, 1H), 5.04 – 4.98 (m, 1H), 4.89 – 4.85 (m, 1H).


$^{13}\text{C NMR}$ (125 MHz, CDCl_3) δ 184.6, 143.8, 140.9, 138.7, 138.7, 136.3, 135.3, 129.1, 128.6, 128.4, 128.4, 127.3, 126.3, 125.7, 125.2, 121.8, 118.5, 116.4, 110.4, 55.1, 51.0.

>99% ee as determined by HPLC (OD-H, *i*-PrOH /*n*-hexane = 10/90, flow rate = 1.0 mL/min, $\lambda = 254 \text{ nm}$) $t_R = 20.1 \text{ min}$ (major), 24.3 min (minor).

HRMS (ESI) m/z: [M + H]⁺ Calcd for $\text{C}_{25}\text{H}_{22}\text{NO}$ 368.1645; Found 368.1645.

VI. Enantiodivergent Synthesis of Compound 9a-d

1-benzyl-3-((R)-1-(3-methoxyphenyl)allyl)-5-((R)-1-phenylallyl)-1H-indole (9a)



Yellowish oil, 79.9 mg, yield (85%); $[\alpha]_D^{20} = +3.7$ (c 1.25, CHCl₃);


¹H NMR (500 MHz, CDCl₃) δ 7.30 – 7.19 (m, 7H), 7.17 – 7.11 (m, 4H), 7.11 – 7.06 (m, 2H), 6.97 – 6.93 (m, 1H), 6.89 – 6.86 (m, 1H), 6.84 – 6.81 (m, 1H), 6.81 – 6.78 (m, 1H), 6.76 – 6.72 (m, 1H), 6.34 – 6.24 (m, 2H), 5.21 (s, 2H), 5.17 – 5.13 (m, 2H), 5.09 – 5.03 (m, 1H), 4.97 – 4.92 (m, 1H), 4.92 – 4.87 (m, 1H), 4.77 – 4.71 (m, 1H), 3.73 (s, 3H).

¹³C NMR (125 MHz, CDCl₃) δ 159.6, 145.0, 144.2, 141.5, 140.4, 137.8, 135.8, 134.0, 129.2, 128.7, 128.6, 128.2, 127.6, 127.5, 126.9, 126.7, 126.0, 122.9, 120.9, 119.6, 117.5, 115.6, 115.4, 114.2, 111.6, 109.6, 55.1, 50.1, 47.0.

>20/1 dr as determined by HPLC (OD-H, i-PrOH /n-hexane = 1/99, flow rate = 1.0 mL/min, λ = 254 nm) t_R = 25.1 min (major), 18.7 min (minor), 21.5 min (minor), 23.8 min (minor).

HRMS (ESI) m/z: [M + H]⁺ Calcd for C₃₄H₃₂NO 470.2478; Found 470.2479.

1-benzyl-3-((S)-1-(3-methoxyphenyl)allyl)-5-((R)-1-phenylallyl)-1H-indole (9b)



Yellowish oil, 79.9 mg, yield (85%); $[\alpha]_D^{20} = -18.1$ (c 1.25, CHCl₃);


¹H NMR (500 MHz, CDCl₃) δ 7.30 – 7.19 (m, 7H), 7.19 – 7.14 (m, 3H), 7.14 – 7.10 (m, 1H), 7.09 – 7.05 (m, 2H), 6.97 – 6.92 (m, 1H), 6.89 – 6.85 (m, 1H), 6.84 – 6.82 (m, 1H), 6.81 – 6.75 (m, 1H), 6.74 – 6.73 (m, 1H), 6.35 – 6.23 (m, 2H), 5.19 (s, 2H), 5.17 – 5.11 (m, 2H), 5.10 – 5.03 (m, 1H), 4.97 – 4.92 (m, 1H), 4.92 – 4.87 (m, 1H), 4.77 – 4.71 (m, 1H), 3.73 (s, 3H).

¹³C NMR (125 MHz, CDCl₃) δ 159.6, 145.0, 144.2, 141.5, 140.4, 137.8, 135.8, 134.0, 129.2, 128.7, 128.6, 128.2, 127.6, 127.5, 126.9, 126.7, 126.0, 122.9, 120.9, 119.6, 117.5, 115.6, 115.4, 114.2, 111.6, 109.6, 55.1, 55.1, 50.1, 47.0.

>20/1 *dr* as determined by HPLC (OD-H, *i*-PrOH /*n*-hexane = 1/99, flow rate = 1.0 mL/min, λ = 254 nm) t_R = 22.0 min (major), 19.8 min (minor), 25.7 min (minor), 26.4 min (minor).

HRMS (ESI) m/z: [M + H]⁺ Calcd for C₃₄H₃₂NO 470.2478; Found 470.2476.

1-benzyl-3-((R)-1-(3-methoxyphenyl)allyl)-5-((S)-1-phenylallyl)-1H-indole (9c)



Yellowish oil, 78.0 mg, yield (83%); [α]_D²⁰ = +16.8 (c 1.25, CHCl₃);


¹H NMR (500 MHz, CDCl₃) δ 7.30 – 7.19 (m, 7H), 7.18 – 7.14 (m, 3H), 7.13 – 7.10 (m, 1H), 7.09 – 7.05 (m, 2H), 6.96 – 6.92 (m, 1H), 6.89 – 6.86 (m, 1H), 6.85 – 6.82 (m, 1H), 6.80 – 6.77 (m, 1H), 6.76 – 6.72 (m, 1H), 6.33 – 6.24 (m, 2H), 5.20 (s, 2H), 5.17 – 5.12 (m, 2H), 5.09 – 5.03 (m, 1H), 4.97 – 4.91 (m, 1H), 4.91 – 4.86 (m, 1H), 4.77 – 4.72 (m, 1H), 3.73 (s, 3H).

¹³C NMR (125 MHz, CDCl₃) δ 159.6, 145.0, 144.2, 141.5, 140.4, 137.8, 135.9, 134.0, 129.3, 128.7, 128.6, 128.3, 127.6, 127.5, 126.9, 126.7, 126.1, 122.9, 120.9, 119.6, 117.5, 115.7, 115.4, 114.2, 111.7, 109.6, 55.2, 55.1, 50.1, 47.0.

>20/1 *dr* as determined by HPLC (OD-H, *i*-PrOH /*n*-hexane = 1/99, flow rate = 1.0 mL/min, λ = 254 nm) t_R = 18.4 min (major), 21.8 min (minor), 24.1 min (minor), 24.6 min (minor).

HRMS (ESI) m/z: [M + H]⁺ Calcd for C₃₄H₃₂NO 470.2478; Found 470.2475.

1-benzyl-3-((S)-1-(3-methoxyphenyl)allyl)-5-((S)-1-phenylallyl)-1H-indole (9d)



Yellowish oil, 79.0 mg, yield (84%); $[\alpha]_D^{20} = -5.86$ (c 1.25, CHCl₃);


¹H NMR (500 MHz, CDCl₃) δ 7.30 – 7.20 (m, 7H), 7.18 – 7.11 (m, 4H), 7.10 – 7.05 (m, 2H), 6.97 – 6.93 (m, 1H), 6.89 – 6.85 (m, 1H), 6.84 – 6.77 (m, 2H), 6.77 – 6.70 (m, 1H), 6.35 – 6.23 (m, 2H), 5.21 (s, 2H), 5.17 – 5.12 (m, 2H), 5.08 – 5.03 (m, 1H), 4.98 – 4.92 (m, 1H), 4.92 – 4.86 (m, 1H), 4.76 – 4.70 (m, 1H), 3.73 (s, 3H).

¹³C NMR (125 MHz, CDCl₃) δ 159.6, 145.0, 144.2, 141.5, 140.4, 137.8, 135.9, 134.0, 129.3, 128.7, 128.6, 128.3, 127.6, 127.5, 126.9, 126.7, 126.1, 122.9, 120.9, 119.6, 117.5, 115.7, 115.4, 114.2, 111.7, 109.6, 55.2, 55.1, 50.1, 47.0.

>20/1 *dr* as determined by HPLC (OD-H, *i*-PrOH /*n*-hexane = 1/99, flow rate = 1.0 mL/min, λ = 254 nm) t_R = 24.1 min (major), 18.0 min (minor), 20.3 min (minor), 22.5 min (minor).


HRMS (ESI) m/z: [M + H]⁺ Calcd for C₃₄H₃₂NO 470.2478; Found 470.2477.

VII. Synthesis of Chiral Analogue 11



The synthetic protocol of substituted indolines were accorded to the relevant literature. An oven-dried Schlenk flask was equipped with stir bar and allyl indole (0.2 mmol, 1.0 equiv), followed by anhydrous THF (1.0 mL). The organic mixture was cooled at 0°C and 9-BBN (0.9 mmol, 0.5 M in THF, 4.5 equiv) was added dropwise via syringe over 5 min. The mixture was warmed to room temperature and stirred for 12 h, followed by the addition of $\text{NaBO}_3 \cdot 4\text{H}_2\text{O}$ (2 mmol, 10 equiv) and distilled water (1.0 mL). The mixture was reacted for another 3 h. After completion, the homogeneous solution was diluted in water and extracted with Et_2O 3 times. The combined organic phase was washed with water and brine, dried over Na_2SO_4 , filtrated and concentrated *in vacuo*. The residue was purified by flash chromatography (PE/EA = 8/1) to yield the terminal product **9** as a white solid.

(R)-3-(1-benzyl-2-methyl-1H-indol-5-yl)-3-phenylpropan-1-ol (10)




White solid, 62.5 mg, yield (88%); mp. = 116.7–118.0 °C; $[\alpha]_D^{20} = -2.4$ (c 1.25, CHCl_3);

^1H NMR (500 MHz, CDCl_3) δ 7.46 – 7.43 (m, 1H), 7.31 – 7.19 (m, 7H), 7.16 – 7.06 (m, 2H), 6.98 – 6.94 (m, 3H), 6.27 – 6.23 (m, 1H), 5.23 (s, 2H), 4.18 (t, $J = 7.9$ Hz, 1H), 3.62 (t, $J = 6.4$ Hz, 2H), 2.39 – 2.31 (m, 2H), 2.33 (s, 3H).

^{13}C NMR (125 MHz, CDCl_3) δ 145.7, 137.9, 137.1, 136.0, 135.6, 128.8, 128.4, 128.3, 127.9, 127.3, 126.1, 126.0, 121.2, 118.5, 109.3, 100.3, 61.6, 47.6, 46.6, 38.8, 12.8.


>99% ee as determined by HPLC (OD-H, *i*-PrOH /*n*-hexane = 10/90, flow rate = 1.0 mL/min, $l = 254$ nm) $t_R = 44.7$ min (major), 49.7 min (minor).

HRMS (ESI) m/z: [M + H]⁺ Calcd for C₂₅H₂₆NO 356.2009; Found 356.2011.



To a dry 25 mL round-bottom flask equipped with a stir bar under Ar atmosphere were added alcohol (0.1 mmol, 1.0 equiv), TsCl (0.11 mmol, 1.1 equiv), DMAP (0.01 mmol, 0.1 equiv) and DCM (1 mL, 0.1 M), followed by the addition of trimethylamine (0.15 mmol, 1.5 equiv). The reaction was stirred for 4 h at room temperature. After completion, the solution was washed with saturated aqueous NaHCO₃ and water. The organic layer was reextracted with DCM twice and the combined organic phases were separated, dried over Na₂SO₄, filtrated and concentrated *in vacuo*. The residue was purified by flash chromatography to give the desired product **10** as a reddish oil.

(R)-3-(1-benzyl-2-methyl-1H-indol-5-yl)-3-phenylpropyl 4-methylbenzenesulfonate (11)



Reddish oil, 46.4 mg, yield (91%); $[\alpha]_D^{20} = +2.2$ (c 1.25, CHCl₃);

¹H NMR (500 MHz, CDCl₃) δ 7.73 – 7.67 (m, 2H), 7.30 – 7.09 (m, 12H), 7.05 – 7.02 (m, 1H), 6.97 – 6.93 (m, 2H), 6.85 – 6.80 (m, 1H), 6.25 – 6.20 (m, 1H), 5.23 (s, 2H), 4.08 (t, *J* = 7.9 Hz, 1H), 3.99 (td, *J* = 6.3, 1.1 Hz, 2H), 2.44 – 2.38 (m, 2H), 2.39 (s, 2H), 2.33 (s, 3H).

¹³C NMR (125 MHz, CDCl₃) δ 144.5, 144.5, 137.8, 137.1, 136.1, 134.3, 133.1, 129.8, 128.8, 128.4, 128.2, 127.9, 127.8, 127.3, 126.1, 126.0, 121.0, 118.4, 109.3, 100.3, 69.2, 46.7, 46.5, 35.06, 21.63, 12.8.

99% *ee* as determined by HPLC (AD-H, *i*-PrOH /*n*-hexane = 10/90, flow rate = 1.0 mL/min, λ = 254 nm) t_R = 20.4 min (major), 22.0 min (minor).

HRMS (ESI) m/z: [M + H]⁺ Calcd for C₃₂H₃₂NO₃S 510.2097; Found 510.2099.

VIII. Absolute Configuration of 3a




Figure S1. Experimental (solid red line, CH₃CN) and calculated (dashed blue line) ECD spectra of compound **3a**.

The absolute configuration is *R*.

Computational details

There are 16 conformations of compound **3a** as shown in Fig. S2. The structures were optimized with the PBE0 functional⁷ at the 6-311G(d,p) basis set with the IEFPCM solvation model⁸ in CH₃CN. Subsequent frequency calculations were performed to confirm the structures are local minima. The obtained Gibbs free energy corrections were approximately used as corrections in vacuum. More accurate gas phase single point energies were computed at the PBE0/def2-TZVPP level. The solvation free energies were calculated from the difference between M05-2X⁹/6-31G(d) and M05-2X/6-31G(d)/SMD¹⁰/CH₃CN single point energies. The relative Gibbs free energies and populations of the 16 conformations are listed in Table S1. Calculations of the ECD spectra were performed using the time-dependent density functional theory (TD-DFT) at the PBE0/def2-TZVP/IEFPCM/CH₃CN level (solving for 20 states). All calculations were performed using Gaussian 16 program.¹¹




Figure S2. Optimized structures and relative populations of the 16 conformations.

Table S1. Relative Gibbs free energies and populations of the 16 conformations.

Conformation	ΔG (kcal/mol)	Population
1	0.00	19.92%
2	0.44	9.52%
3	0.09	17.23%
4	0.28	12.44%
5	0.30	11.94%
6	0.45	9.26%
7	0.64	6.76%
8	0.26	12.92%
9	0.64	6.76%
10	0.66	6.51%
11	0.44	9.41%
12	0.40	10.06%
13	0.65	6.68%
14	0.78	5.35%
15	0.48	8.91%
16	0.47	8.99%

References:

1. a) Herrera, A.; Linden, A.; Heinemann, F. W.; Brachvogel, R.-C.; Delius, M. V.; Dorta, R. Optimized Syntheses of Optically Pure P-Alkene Ligands: Crystal Structures of a Pair of P-Stereogenic Diastereomers. *Synthesis* **2016**, *48*, 1117-1121. b) Hilpert, L. J.; Breit, B. Rhodium-Catalyzed Parallel Kinetic Resolution of Racemic Internal Allenes Towards Enantiopure Allylic 1,3-Diketones. *Angew. Chem., Int. Ed.* **2019**, *58*, 9939-9943. c) Mariz, R.; Briceño, A.; Dorta, R.; Dorta R. Chiral Dibenzazepine-Based P-Alkene Ligands and Their Rhodium Complexes: Catalytic Asymmetric 1,4 Additions to Enones. *Organometallics*. **2008**, *27*, 6605-6613.
2. a) Estopiñá-Durán, S.; Mclean, E. B.; Donnelly, L. J.; Hockin, B. M.; Taylor, J. E. Arylboronic Acid Catalyzed C-Alkylation and Allylation Reactions Using Benzylic Alcohols. *Org. Lett.* **2020**, *22*, 7547-7551. b) Spoehrle, S. S. M.; West, T. H.; Taylor, J. E.; Slawin, A. M. Z.; Smith, A. D. Tandem Palladium and Isothiourea Relay Catalysis: Enantioselective Synthesis of α -Amino Acid Derivatives via Allylic Amination and [2,3]-Sigmatropic Rearrangement. *J. Am. Chem. Soc.* **2017**, *139*, 11895-11902.
3. a) Kawauchi, D.; Noda, K.; Komatsu, Y.; Yoshida, K.; Ueda, H.; Tokuyama, H. Aerobic Dehydrogenation of *N*-Heterocycles with Grubbs Catalyst: Its Application to Assisted-Tandem Catalysis to Construct *N*-Containing Fused Heteroarenes. *Chem. Eur. J.* **2020**, *26*, 15793-15798. b) Zhang, D.-L.; Iwai, T.; Sawamura, M. Ir-Catalyzed Reversible Acceptorless Dehydrogenation/Hydrogenation of *N*-Substituted and Unsubstituted Heterocycles Enabled by a Polymer-Cross-Linking Bisphosphine. *Org. Lett.* **2020**, *22*, 5240-5245. c) Dasa, B. G.; Ghorai, P. The direct reductive amination of electron-deficient amines with aldehydes: the unique reactivity of the Re_2O_7 catalyst. *Chem. Commun.* **2012**, *48*, 8276-8278. d) Ertugrul, B.; Kilic, H.; Lafzi, F.; Saracoglu, N. Access to C5-Alkylated Indolines/Indoles via Michael-Type Friedel-Crafts Alkylation Using Aryl-Nitroolefins. *J. Org. Chem.* **2018**, *83*, 9018-9038.
4. a) Takamura, H. Recent Topics of the Stereodivergent Synthesis of Natural Products. *Tetrahedron Lett.* **2018**, *59*, 955-966. b) Krautwald, S.; Carreira, E. M. Stereodivergence in Asymmetric Catalysis. *J. Am. Chem. Soc.* **2017**, *139*, 5627-5639. c) Kaldre, D.; Klose, I.; Maulide, N. Stereodivergent Synthesis of 1,4-dicarbonyls by Traceless Charge-accelerated Sulfonium Rearrangement. *Science*, **2018**, *361*, 664-667. d) Liu, X.-J.; Jin, S.; Zhang, W.-Y.; Liu, Q.-Q.; Zhen, C.; You, S.-L. Sequence-Dependent Stereodivergent Allylic Alkylation/Fluorination of Acyclic Ketones.




Angew. Chem., Int. Ed. **2020**, *59*, 2039-2043. e) Li, X.-Y.; Hall, D. G. Stereodivergent Asymmetric Synthesis of α,β -Disubstituted β -Aminoalkylboronic Acid Derivatives via Group-Selective Protodeboronation Enabling Access to the Elusive Anti Isomer. *J. Am. Chem. Soc.* **2020**, *142*, 9063-9069. f) Gao, T.-T.; Zhang, W.-W.; Sun, X.; Lu, H.-X.; Li, B.-J. Stereodivergent Synthesis through Catalytic Asymmetric Reversed Hydroboration. *J. Am. Chem. Soc.* **2019**, *141*, 4670-4677. g) Sandmeier, T.; Krautwald, S.; Zipfel, H. F.; Carreira, E. M. Stereodivergent Dual Catalytic α -Allylation of Protected α -Amino- and α -Hydroxyacetaldehydes. *Angew. Chem., Int. Ed.* **2015**, *54*, 14363-14367. h) Krautwald, S.; Sarlah, D.; Schafroth, M. A.; Carreira, E. M. Enantio- and Diastereodivergent Dual Catalysis: α -Allylation of Branched Aldehydes. *Science* **2013**, *340*, 1065-1068. i) Krautwald, S.; Schafroth, D.; Sarlah, D.; Carreira, E. M. Stereodivergent α -Allylation of Linear Aldehydes with Dual Iridium and Amine Catalysis. *J. Am. Chem. Soc.* **2014**, *136*, 3020-3023. j) Zhang, J.-C.; Huo, X.-H.; Li, B.-W.; Chen, Z.-L.; Zou, Y.-S.; Sun, Z.-L.; Zhang, W.-B. Enantioselective and Diastereodivergent Access to α -Substituted α -Amino Acids via Dual Iridium and Copper Catalysis. *Adv. Synth. Catal.* **2019**, *361*, 1130-1139. k) Huo, X.-H.; Zhang, J.-C.; Fu, J.-K.; He, R.; Zhang, W.-B. Ir/Cu Dual Catalysis: Enantio- and Diastereodivergent Access to α,α -Disubstituted α -Amino Acids Bearing Vicinal Stereocenters. *J. Am. Chem. Soc.* **2018**, *140*, 2080-2084. l) Huo, X.-H.; He, R.; Zhang, X.; Zhang, W.-B. An Ir/Zn Dual Catalysis for Enantio- and Diastereodivergent α -Allylation of α -Hydroxyketones. *J. Am. Chem. Soc.* **2016**, *138*, 11093-11096.



5. a) Iyer, P.; Lucas, M. C.; Schoenfeld, R. C.; Villa, M.; Weikert, R. J. US20070123527, **2007**. b) Lucas, M. C.; Carter, D. S.; Cai, H.-Y.; Lee, E. K.; Schoenfeld, R. C.; Steiner, S.; Villa M.; Weikert, R. J.; Iyer, P. S.; Med., Bioorg. Novel, Achiral Aminoheterocycles as Selective Monoamine Reuptake Inhibitors. *Chem. Lett.* **2009**, *19*, 4630-4633.




6. a) Altenbach, R. J.; Black, L. A.; Strakhova, M. I.; Manelli, A. M.; Carr, T. L.; Marsh, K. C.; Wetter, J. M.; Wensink, E. J.; Hsieh, G. C.; Honore, P.; Garrison, T. R.; Brioni, J. D.; Cowart, M. D. Diaryldiamines with Dual Inhibition of the Histamine H3 Receptor and the Norepinephrine Transporter and the Efficacy of 4-(3-(Methylamino)-1-phenylpropyl)-6-(2-(pyrrolidin-1-yl)ethoxy)naphthalen-1-ol in Pain. *J. Med. Chem.* **2010**, *53*, 7869-7873. b) Ertugrul, B.; Kilic, H.; Lafzi, F.; Saracoglu, N. Access to C5-Alkylated Indolines/Indoles via Michael-Type Friedel-Crafts Alkylation Using Aryl-Nitroolefins. *J. Org. Chem.* **2018**, *83*, 9018-9038.




7. Adamo, C.; Barone, V., Toward reliable density functional methods without adjustable parameters: The PBE0 model. *J. Chem. Phys.* 1999, 110, 6158-6170.
8. Tomasi, J.; Mennucci, B.; Cammi, R., Quantum Mechanical Continuum Solvation Models. *Chem. Rev.* 2005, 105, 2999-3094.
9. Zhao, Y.; Schultz, N. E.; Truhlar, D. G., Design of Density Functionals by Combining the Method of Constraint Satisfaction with Parametrization for Thermochemistry, Thermochemical Kinetics, and Noncovalent Interactions. *J. Chem. Theory Comput.* 2006, 2, 364-382.
10. Marenich, A. V.; Cramer, C. J.; Truhlar, D. G., Universal Solvation Model Based on Solute Electron Density and on a Continuum Model of the Solvent Defined by the Bulk Dielectric Constant and Atomic Surface Tensions. *J. Phys. Chem. B* 2009, 113, 6378-6396.
11. Frisch, M. J.; Trucks, G. W.; Schlegel, H. B.; Scuseria, G. E.; Robb, M. A.; Cheeseman, J. R.; Scalmani, G.; Barone, V.; Petersson, G. A.; Nakatsuji, H.; Li, X.; Caricato, M.; Marenich, A. V.; Bloino, J.; Janesko, B. G.; Gomperts, R.; Mennucci, B.; Hratchian, H. P.; Ortiz, J. V.; Izmaylov, A. F.; Sonnenberg, J. L.; Williams; Ding, F.; Lipparini, F.; Egidi, F.; Goings, J.; Peng, B.; Petrone, A.; Henderson, T.; Ranasinghe, D.; Zakrzewski, V. G.; Gao, J.; Rega, N.; Zheng, G.; Liang, W.; Hada, M.; Ehara, M.; Toyota, K.; Fukuda, R.; Hasegawa, J.; Ishida, M.; Nakajima, T.; Honda, Y.; Kitao, O.; Nakai, H.; Vreven, T.; Throssell, K.; Montgomery Jr., J. A.; Peralta, J. E.; Ogliaro, F.; Bearpark, M. J.; Heyd, J. J.; Brothers, E. N.; Kudin, K. N.; Staroverov, V. N.; Keith, T. A.; Kobayashi, R.; Normand, J.; Raghavachari, K.; Rendell, A. P.; Burant, J. C.; Iyengar, S. S.; Tomasi, J.; Cossi, M.; Millam, J. M.; Klene, M.; Adamo, C.; Cammi, R.; Ochterski, J. W.; Martin, R. L.; Morokuma, K.; Farkas, O.; Foresman, J. B.; Fox, D. J. *Gaussian 16 Rev. A.03*, Wallingford, CT, 2016.


IX. Data of NMR Spectra:























CDCl₃; 500Hz





CDCl₃; 125Hz














$\text{CDCl}_3; 471\text{Hz}$









$\text{CDCl}_3; 500\text{Hz}$














































CDCl_3 ; 500Hz










CDCl_3 ; 500Hz



























CDCl_3 ; 500Hz







CDCl_3 ; 125Hz










CDCl₃; 125Hz



















CDCl_3 ; 500Hz




CDCl_3 ; 125Hz














5d








5e








S93







5f

























S100








CDCl₃; 500Hz





CDCl₃; 125Hz


S102





X. Data of HPLC Chromatography:




Peak#	Ret. Time	Area	Height	Area %	Height %
1	18.227	5272029	202572	54.018	55.981
2	19.272	4487729	159290	45.982	44.019
Total		9759758	361862	100.000	100.000






Peak#	Ret. Time	Area	Height	Area %	Height %
1	18.209	14699	623	0.193	0.233
2	19.067	7597717	266818	99.807	99.767
Total		7612416	267441	100.000	100.000









Peak#	Ret. Time	Area	Height	Area %	Height %
1	4.645	200890	20000	49.745	52.405
2	5.088	202946	18165	50.255	47.595
Total		403836	38165	100.000	100.000









Peak#	Ret. Time	Area	Height	Area %	Height %
1	4.627	996	124	0.286	0.396
2	5.057	347323	31214	99.714	99.604
Total		348319	31338	100.000	100.000



















Peak#	Ret. Time	Area	Height	Area %	Height %
1	12.309	351565	10773	50.324	69.755
2	15.218	347035	4671	49.676	30.245
Total		698600	15444	100.000	100.000




Peak#	Ret. Time	Area	Height	Area %	Height %
1	12.769	1734728	34020	99.927	99.962
2	16.183	1259	13	0.073	0.038
Total		1735987	34033	100.000	100.000










Peak#	Ret. Time	Area	Height	Area %	Height %
1	10.461	2983962	175338	46.844	48.056
2	11.219	3386099	189522	53.156	51.944
Total		6370062	364860	100.000	100.000




Peak#	Ret. Time	Area	Height	Area %	Height %
1	10.092	3961666	244872	99.802	99.761
2	10.849	7851	586	0.198	0.239
Total		3969517	245459	100.000	100.000








Peak#	Ret. Time	Area	Height	Area %	Height %
1	22.222	6416264	129400	49.703	50.445
2	24.633	6493067	127118	50.297	49.555
Total		12909331	256518	100.000	100.000






Peak#	Ret. Time	Area	Height	Area %	Height %
1	22.125	520539	9855	99.685	99.558
2	24.339	1644	44	0.315	0.442
Total		522183	9898	100.000	100.000








Peak#	Ret. Time	Area	Height	Area %	Height %
1	18.859	3565846	118748	50.169	52.709
2	20.526	3541790	106542	49.831	47.291
Total		7107636	225290	100.000	100.000




Peak#	Ret. Time	Area	Height	Area %	Height %
1	18.192	19789	797	1.488	1.622
2	19.654	1309735	48369	98.512	98.378
Total		1329524	49166	100.000	100.000










Peak#	Ret. Time	Area	Height	Area %	Height %
1	9.513	1655432	123878	50.025	51.728
2	10.239	1653758	115600	49.975	48.272
Total		3309190	239479	100.000	100.000





Peak#	Ret. Time	Area	Height	Area %	Height %
1	9.501	66933	5290	0.346	0.394
2	10.222	19268894	1335872	99.654	99.606
Total		19335827	1341162	100.000	100.000




Peak#	Ret. Time	Area	Height	Area %	Height %
1	46.665	1581064	17341	49.379	52.436
2	51.031	1620834	15730	50.621	47.564
Total		3201899	33070	100.000	100.000






Peak#	Ret. Time	Area	Height	Area %	Height %
1	46.588	77494	935	1.310	1.551
2	50.543	5836123	59357	98.690	98.449
Total		5913617	60292	100.000	100.000





Peak#	Ret. Time	Area	Height	Area %	Height %
1	16.172	1173846	23068	49.968	50.761
2	18.622	1175348	22376	50.032	49.239
Total		2349194	45444	100.000	100.000




Peak#	Ret. Time	Area	Height	Area %	Height %
1	16.180	11627	251	0.416	0.466
2	18.529	2784293	53524	99.584	99.534
Total		2795920	53775	100.000	100.000








Peak#	Ret. Time	Area	Height	Area %	Height %
1	5.159	7229405	612320	47.993	51.568
2	5.561	7834065	575086	52.007	48.432
Total		15063470	1187406	100.000	100.000





Peak#	Ret. Time	Area	Height	Area %	Height %
1	5.153	39171	3500	1.050	1.227
2	5.548	3690856	281729	98.950	98.773
Total		3730028	285229	100.000	100.000




Peak#	Ret. Time	Area	Height	Area %	Height %
1	9.445	1468280	93799	49.220	68.516
2	16.251	1514806	43101	50.780	31.484
Total		2983086	136900	100.000	100.000






Peak#	Ret. Time	Area	Height	Area %	Height %
1	9.375	7726090	492792	99.648	99.758
2	16.399	27285	1195	0.352	0.242
Total		7753375	493986	100.000	100.000









Peak#	Ret. Time	Area	Height	Area %	Height %
1	29.978	464249	6128	51.348	56.074
2	40.335	439871	4801	48.652	43.926
Total		904121	10929	100.000	100.000








Peak#	Ret. Time	Area	Height	Area %	Height %
1	30.068	62477	825	0.663	0.819
2	39.512	9366485	99953	99.337	99.181
Total		9428962	100779	100.000	100.000




















Peak#	Ret. Time	Area	Height	Area %	Height %
1	15.704	680556	18992	49.379	47.315
2	17.320	697681	21148	50.621	52.685
Total		1378237	40141	100.000	100.000




Peak#	Ret. Time	Area	Height	Area %	Height %
1	14.128	1013	49	0.170	0.259
2	15.957	595772	18769	99.830	99.741
Total		596784	18818	100.000	100.000









Peak#	Ret. Time	Area	Height	Area %	Height %
1	29.823	161896	1793	50.951	54.688
2	37.133	155853	1486	49.049	45.312
Total		317748	3279	100.000	100.000




Peak#	Ret. Time	Area	Height	Area %	Height %
1	30.394	591139	7908	99.292	99.473
2	37.753	4217	42	0.708	0.527
Total		595356	7949	100.000	100.000





4f




Peak#	Ret. Time	Area	Height	Area %	Height %
1	18.339	890775	26949	49.073	49.435
2	19.741	924420	27565	50.927	50.565
Total		1815195	54514	100.000	100.000






Peak#	Ret. Time	Area	Height	Area %	Height %
1	18.030	6963940	193042	93.160	94.212
2	19.729	511293	11860	6.840	5.788
Total		7475233	204902	100.000	100.000









Peak#	Ret. Time	Area	Height	Area %	Height %
1	12.375	692001	38878	50.101	51.740
2	13.129	689214	36263	49.899	48.260
Total		1381214	75141	100.000	100.000





Peak#	Ret. Time	Area	Height	Area %	Height %
1	12.353	1425537	80376	99.419	99.270
2	13.111	8326	591	0.581	0.730
Total		1433863	80967	100.000	100.000



















Peak#	Ret. Time	Area	Height	Area %	Height %
1	4.777	223810	21101	51.730	53.592
2	5.455	208842	18273	48.270	46.408
Total		432652	39373	100.000	100.000









Peak#	Ret. Time	Area	Height	Area %	Height %
1	4.762	5389	545	1.194	1.422
2	5.449	445843	37808	98.806	98.578
Total		451233	38354	100.000	100.000


























Peak#	Ret. Time	Area	Height	Area %	Height %
1	18.526	1076700	23974	25.365	30.611
2	21.388	1066243	18535	25.119	23.667
3	24.035	837772	17885	19.737	22.837
4	24.860	1264047	17923	29.779	22.885
Total		4244762	78317	100.000	100.000





Peak#	Ret. Time	Area	Height	Area %	Height %
1	18.678	4648	98	0.485	0.699
2	21.534	15550	304	1.621	2.181
3	23.827	817	3	0.085	0.019
4	25.108	938224	13556	97.809	97.101
Total		959238	13961	100.000	100.000






Peak#	Ret. Time	Area	Height	Area %	Height %
1	19.797	1548	48	0.251	0.438
2	21.974	607917	10651	98.460	97.873
3	25.700	350	32	0.057	0.292
4	26.374	7613	152	1.233	1.397
Total		617427	10882	100.000	100.000





Peak#	Ret. Time	Area	Height	Area %	Height %
1	18.442	2689985	60930	99.591	99.541
2	21.745	685	0	0.025	0.001
3	24.083	498	67	0.018	0.109
4	24.547	9874	214	0.366	0.349
Total		2701042	61210	100.000	100.000



Peak#	Ret. Time	Area	Height	Area %	Height %
1	18.011	4335	108	1.728	2.711
2	20.269	610	8	0.243	0.211
3	22.497	197	9	0.079	0.228
4	24.052	245793	3852	97.951	96.849
Total		250936	3978	100.000	100.000





Peak#	Ret. Time	Area	Height	Area %	Height %
1	20.592	104672	3301	50.020	51.421
2	22.108	104589	3119	49.980	48.579
Total		209261	6420	100.000	100.000

